Open Access Full Text Article

Vitamin D deficiency and the risk of tuberculosis: a meta-analysis

Shao-Jun Huang¹ Xian-Hua Wang² Zhi-Dong Liu¹ Wen-Li Cao³ Yi Han¹ Ai-Guo Ma² Shao-Fa Xu¹

¹Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China; ²Department of Nutrition and Food Hygiene, Institute of Human Nutrition, Medical College of Qingdao University, Qingdao, People's Republic of China; ³Department of Pulmonary Medicine, Beijing Geriatric Hospital, Beijing, People's Republic of China

Correspondence: Shao-Fa Xu Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, No 97 Machang, Tongzhou District, Beijing, People's Republic of China Tel +86 10 8950 9326 Email shaofaxu@yahoo.com



Background and aim: To conduct meta-analyses of all published studies on various aspects of association between vitamin D and tuberculosis (TB).

Methods: PubMed and Web of Knowledge were searched for all properly controlled studies on vitamin D and TB. Pooled odds ratio, mean difference or standardized mean difference, and its corresponding 95% confidence interval were calculated with the Cochrane Review Manager 5.3.

Results: A significantly lower vitamin D level was found in TB patients vs controls; vitamin D deficiency (VDD) was associated with an increased risk of TB, although such an association was lacking in the African population and in the human immunodeficiency virus-infected African population. A significantly lower vitamin D level was found in human immunodeficiency virus-TB-coinfected African patients receiving antiretroviral treatment who developed TB-associated immune reconstitution inflammatory syndrome vs those who did not develop TB-associated immune reconstitution inflammatory syndrome. VDD was associated with an increased risk of developing active TB in those subjects with latent TB infection and with an increased risk of tuberculin skin test conversion/TB infection subjects did not reach statistical significance, indicating that VDD was more likely a risk factor than a consequence of TB. This concept was further strengthened by our result that anti-TB treatment did not affect vitamin D level in TB patients receiving the treatment.

Conclusion: Our analyses revealed an association between vitamin D and TB. VDD is more likely a risk factor for TB than its consequence. More studies are needed to determine whether vitamin D supplementation is beneficial to TB prevention and treatment.

Keywords: vitamin D, vitamin D deficiency, tuberculosis, 25-hydroxyvitamin D, metaanalysis

Introduction

Tuberculosis (TB) remains a major public health problem globally. It was estimated that there were 8.7 million reported new TB cases and that 1.4 million people died from TB in 2011.¹ Various factors that could possibly affect the incidence and progression of TB have been reported, one of them is vitamin D deficiency (VDD).¹⁻⁶ Exposure to sunlight is the main source of vitamin D for human and induces the conversion of 7-dehydrocholesterol to vitamin D3 via previtamin D3 in the skin.⁷ Vitamin D3 is then converted to 25-hydroxyvitamin D (25(OH)D) in the liver and is further converted to the bioactive form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in the kidney.⁷ Studies have found that 1,25(OH)2D3 binds to vitamin D receptor (VDR), activates VDR signaling, and induces a series of antimicrobial responses such as induction of autophagy, phagolysosomal fusion, release and activation of the antimicrobial peptide cathelicidin, and killing of intracellular *Mycobacterium tuberculosis*.⁷⁻⁹

Drug Design, Development and Therapy 2017:11 91-102

© 2017 Huag et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraph 4.2 and 5 of our Terms (http://www.dovepress.com/terms.php).

Numerous studies have been conducted to study whether VDD was associated with TB; however, they produced inconsistent and varying results.^{1–6,10–12} There has been one meta-analysis on association between VDD and TB, and it concluded that a lower serum vitamin D level was associated with a higher risk of active TB.¹³ However, it was conducted in 2008 and did not include numerous later studies, and further it did not perform a subgroup analysis based on factors such as ethnicity.

In this study, we performed meta-analyses comparing serum vitamin D levels in TB cases vs controls and on association between VDD and risk of TB with subgroup analysis based on the ethnicity of the study population in order to further elucidate the role of vitamin D level in TB pathogenesis in a larger population pool. Second, assuming VDD is indeed associated with TB, it is still undetermined whether VDD is one of the causes of TB or manifestation of the malnutrition status generally seen in TB patients.¹ In order to explore this question, we further examined the association between vitamin D level/VDD and risk of developing active TB in subjects with latent TB infection (LTBI)/household contacts of TB patients and also the association between VDD and tuberculin skin test (TST) conversion/TB infection conversion (TBIC). An additional analysis was also performed on the effect of anti-TB treatment on vitamin D level in TB subjects for the same purpose. Third, since human immunodeficiency virus (HIV)-infected subjects are more susceptible to TB and have greater mortality and morbidity caused by TB,14 to further clarify whether vitamin D played any role in occurrence and deterioration of TB in HIV-infected subjects, we also analyzed the association between vitamin D level/ VDD and TB in HIV-infected subjects and the association between vitamin D level and risk of developing TB-associated immune reconstitution inflammatory syndrome (TB-IRIS) in HIV-TB-coinfected patients receiving antiretroviral therapy (ART). Finally, although serum 25(OH)D is the commonly used measure of vitamin D status in a subject,⁷ 1,25(OH)2D3 is the actual bioactive form of vitamin D that induces antimicrobial response,⁷ and so we also performed a meta-analysis on the association between 1,25(OH)2D3 and TB in order to determine whether there was any change of 1,25(OH)2D3 level in TB subjects compared to control without TB.

Methods

Search strategy, inclusion and exclusion criteria, and data extraction

PubMed/Medline and Web of Science (Web of Knowledge) databases were searched to identify all studies relating to vitamin D and TB using the following search terms: "vitamin D",

92

"VDD", "hypovitaminosis D", "tuberculosis", "TB", "25-hydroxyvitamin D", and "1,25-dihydroxyvitamin D".

All properly controlled studies published in English on vitamin D and TB were potentially eligible for inclusion in our meta-analysis. We excluded reviews, meeting abstracts, and case-only studies.

Relevant data from each included study were extracted. Among the data extracted, relevant group meanvalues (standard deviations, SDs) were extracted from each included study whenever possible. When relevant values were presented only as median (interquartile range), mean (SD) was approximated as median (interquartile range/1.35);¹⁵ when relevant values were presented only as median (range), mean (SD) was approximated as median (range/4);¹⁶ when relevant values were presented only as median (range/3);¹⁶ when relevant values were presented only as mean values (standard errors, SEs), SD was extracted as SE × square root of sample size;¹⁷ and when relevant values were presented only as meanvalues (confidence intervals, CIs), SD was extracted as square root of sample size × (upper limit – lower limit)/(2× *Y*), where *Y* is the *t* value from a size equal to sample size minus 1.¹⁷

Quality of the studies

Each study's adequacy in three key areas (methodological, clinical, and statistical) was evaluated first. Then each study was screened with the Newcastle–Ottawa Scale.¹⁸

Statistical analysis

Cochrane Review Manager (RevMan 5.3, Copenhagen, Denmark, The Nordic Cochrane Centre) was used to perform all statistical analysis. Continuous outcomes were analyzed using mean difference (MD) or standardized MD (SMD), while dichotomous outcome was analyzed using pooled odds ratio (OR). Pooled OR and MD/SMD with their corresponding 95% CI were calculated with a random-effect model because this model assumes a genuine diversity in the results caused by between-studies heterogeneity and incorporates a between-studies variance into the calculation accordingly.¹⁹ The Z test was used to assess the statistical significance of the pooled OR and MD/SMD. Betweenstudies heterogeneity was assessed with the Cochran Q statistic-based chi-square (χ^2) test,²⁰ and I^2 index was the tool used to assess the heterogeneity, where a I^2 value around 25%, 50%, and 75% indicated a low, moderate, and large heterogeneity, respectively.²¹ Finally, if no heterogeneity was found using the random-effect model $(I^2=0)$, data were analyzed again using a fixed-effect model. Statistical significance was considered with a *P*-value of <0.05, except for the Q statistic where a P-value of <0.10 indicated statistically significance.


Subpopulation analysis was performed according to the ethnicity of the subjects. In addition, funnel plots were used to evaluate the publication bias in each meta-analysis.

Results Eligible studies and characteristics of the studies

Figure 1 illustrates our search process and results. From a total of 723 potentially eligible articles, 685 were excluded because they were irrelevant to our topic here, reviews, meeting abstracts, or case-only studies, or contained no detailed data needed for our meta-analysis. A total of 38 articles were included in our meta-analysis.^{1,2,4,5,11,12,14,22-52}

Vitamin D level was significantly lower in TB patients vs controls, and VDD was associated with an increased risk of TB

A total of 25 studies with 3,599 TB cases and 3,063 control subjects were included in our analysis of serum/plasma 25(OH)D level in TB patients vs control (Figure 2A).^{1,4,5,11,12,14,22–28,30,35–44,46} Our analysis with a random-effect model showed a significantly lower serum/plasma 25(OH)D level in TB patients vs controls (MD =–13.05; 95% CI =[-19.02, -7.08]; P<0.0001; P=96) (Figure 2A). Subgroup analysis showed similar result for the Asian population (MD =–14.64; 95% CI =[-20.15, -9.13]; P<0.00001; P=89); however, there was no such significant



Studies included in the meta-analysis of serum/plasma 25-hydroxyvitamin D (25(OH)D) level in tuberculosis (TB) patients vs control, and of vitamin D deficiency (VDD) and TB, N=21, and 23, respectively.

Studies included in the meta-analysis of serum 25(OH)D level in active TB subject vs latent TB infection (LTBI) subjects/household contacts of active TB patients, of VDD and number of LTBI subjects or household contacts of TB patients developing active TB, and of VDD and risk of tuberculin skin test (TST) conversion/TB infection conversion (TBIC), N=4, 5, and 3, respectively.

Studies included in the meta-analysis of serum 25(OH)D level in HIV-TB coinfected patients vs HIV patients without TB, of VDD and risk of TB in HIV-infected patients, and of 25(OH)D level and risk of developing TB-associated immune reconstitution inflammatory syndrome (TB-IRIS) in HIV-TB co-infected patients receiving antiretroviral therapy (ART), N=4, 4, and 3, respectively.

Studies included in the meta-analysis of the effect of 1–4 months of anti-TB treatment on 25(OH)D level in TB patients, of the effect of a full course of anti-TB treatment on 25(OH)D level in TB patients, and of 25(OH)D level in TB patients after anti-TB treatment vs control without TB, N=3, 4, and 4, respectively.

Studies included in the meta-analysis of the level of serum/plasma 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in TB patients vs control, N=4

Figure I Flow diagram of the publication selection process.

Study or subgroup Asian		TB Mean	SD	Total	Control Mean	SD	Total	Weight (%)	Mean difference random, 95% Cl	IV,	Year		Mean diff random, 9	erence IV, 95% CI
Asian Grange et al ²³ Davies et al ²⁶ Chan et al ²⁷ Wilkinson et al ⁴ Sasidharan et al ²⁸		65.75 69.5 46.5 12 26.75	21.69 24.5 18.5 10.74 18.13	40 51 22 103 35	69.5 95.5 52.25 17 48.5	19.12 29.25 15.75 10.96 30.63	38 51 23 42 16	3.6 3.5 3.5 3.9 3.1	-3.75 (-12.81, 5.3 -26.00 (-36.47, - -5.75 (-15.81, 4.3 -5.00 (-8.91, -1.0 -21.75 (-37.92, -	15.53) 31) 09)	1985 1988 1994 2000 2002	-		-
Rathored et al ³⁸ MDR-TB cas Koo et al ³⁷		13.5 34.75	10 24.07	354 116	34.9 33	26.2 17.96	205 86	3.9 3.8	-21.40 (-25.13, - 1.75 (-4.05, 7.55)	17.67)	2012 2012		+ -	-
Chaudhary et al ³⁹ diabetic ca Chaudhary et al ³⁹ cases with Kim et al ⁵⁵ Joshi et al ⁵⁶ Hong et al ⁴⁶		39.9 40.28 33 37.14 24.65	32.18 22.9 21.58 19.05 12.89	40 30 165 25 94	48.55 73.68 46.75 76.19 40.08	28.3 45.72 20.83 28.57 14.67	46 39 197 25 282	3.3 3.0 3.9 3.3 3.9	-8.65 (-21.55, 4.2 -33.40 (-49.92, - -13.75 (-18.14, - -39.05 (-52.51, - -15.43 (-18.55, -	16.88) 9.36) 25.59)	2013 2013 2013 2013 2014	_		-
Subtotal (95% CI) Heterogeneity: τ^2 =72.43; χ^2 =	-06 49 df=11			1,075	40.00	14.07	1,050	42.6	-14.64 (-20.15, -		2014		٠	
Test for overall effect: Z=5.2			01), <i>1</i> =03	770										
African Davies et al ²⁴ Wejse et al ⁵		39.75 78.3	18.13 22.6	15 362	65.5 85.3	22.13 34.8	15 494	3.2 3.9	-25.75 (-40.23, - -7.00 (-10.85, -3		1987 2007	-		
Nansera et al ¹⁴		60	27.5	50	70	27.5	50	3.5	-10.00 (-20.78, 0		2011			-
Martineau et al35		34.4	20.8	192	55	23	178	3.8	-20.60 (-25.08, -		2011		-	
Conesa-Botella et al ^{12,51} HIV- Conesa-Botella et al ^{12,51} HIV-		81 78	32.59 22.22	92 27	79 71	28.15 20	20 23	3.2 3.4	2.00 (-12.02, 16.0 7.00 (-4.71, 18.71		2012 2012		-	
Steenhoff et al ¹¹	unimecteu	35.1	11.19	19	38.3	20 10.15	23 19	3.4	-3.20 (-9.99, 3.59		2012			
Mastala et al43		59.7	28.48	161	84.2	40.6	157	3.7	-24.50 (-32.23, -		2013			
Friis et al40		110.9	35.7	1,223	84.4	25.6	347	3.9	26.50 (23.14, 29.8		2013			-
Subtotal (95% CI) Heterogeneity: τ^2 =468.91; χ^2	2=389.17, df=8	3 (<i>P</i> <0.000	001); <i>P</i> =9	2,141 98%			1,303	32.4	-6.05 (-20.54, 8.4	13)			-	
Test for overall effect: Z=0.83 Ethnicity unspecified	2 (P=0.41)													
Davies et al ²²		16	18	40	27.25	30.88	40	3.5	–11.25 (–22.33, –	0.17)	1985			
Davies et al ²⁵ patient group C		22	14	14	26.5	16	14	3.5	-4.50 (-15.64, 6.6		1987		-	-
Davies et al ²⁵ patient group A Sita-Lumsden et al ³⁰	Apr–Sep	14.25 20.1	1.19 12.67	13 178	33.35 30.8	29.38 19.38	13 130	3.1 3.9	-19.10 (-35.08, - -10.70 (-14.52, -		1987 2007	-	-	
Gray et al ³⁶		29.6	11.16	11	43.5	25.47	236	3.7	-13.90 (-21.25, -		2007		_	
Srinivasan et al44		67.45	10.71	22	117.43	18.4	22	3.6	-49.98 (-58.88, -		2013			
Iftikhar et al41		55.58	17.03	105	73.18	22.23	255	3.9	-17.60 (-21.85, -		2013		+	
				383			710	25.0	–18.15 (–27.28, –	9.02)			-	
Subtotal (95% CI)													-	
Subtotal (95% CI) Heterogeneity: τ^2 =129.43; χ^2 Test for overall effect: Z=3.90		(<i>P</i> <0.000	01); <i>l</i> ²=91										•	
Heterogeneity: τ^2 =129.43; χ^2 Test for overall effect: Z=3.9		(<i>P</i> <0.000	01); <i>P</i> =91	1%										
Heterogeneity: 7 ² =129.43; 2 ['] Test for overall effect: Z=3.94 Total (95% CI)	0 (<i>P</i> <0.0001)			1% 3,599			3,063	100	-13.05 (-19.02, -	7.08)			•	
Heterogeneity: τ^2 =129.43; χ^2 Test for overall effect: Z=3.9	0 (P<0.0001) ² =713.86, df=2 8 (P<0.0001)	27 (<i>P</i> <0.00	0001); <i>P</i> =	1% 3,599 =96%			3,063	100	-13.05 (-19.02, -	7.08)	-100	–50 Lower vit D in TE	•	0 50 Lower vit D in control
Heterogeneity: t^2 =129.43; χ' Test for overall effect: Z=3.94 Total (95% CI) Heterogeneity: t^2 =235.82; χ' Test for overall effect: Z=4.21 Test for subgroup differences Study or subgroup	0 (P<0.0001) ² =713.86, df=2 8 (P<0.0001)	27 (<i>P</i> <0.00	0001);	1% 3,599 =96%	Total	W (?	leight	Odds		7.08) Year	-100	Lower vit D in TE Od	3 ds ratio	Lower
Heterogeneity: τ^2 =129.43; χ' Test for overall effect: Z=3.91 Total (95% CI) Heterogeneity: τ^2 =235.82; χ' Test for overall effect: Z=22 Test for subgroup differences Study or subgroup Asian	0 (<i>P</i> <0.0001) ² =713.86, <i>df</i> =2 8 (<i>P</i> <0.0001) s: χ ² =1.92, <i>df</i> = TB	27 (P<0.00 =2 (P=0.38	0001);	1% 3,599 ⊧96% €ontrol €vents	Total 38		leight %)	Odds M–H,	ratio random, 95% Cl		-100	Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: τ^2 =129.43; χ' Test for overall effect: Z=3.91 Total (95% CI) Heterogeneity: τ^2 =235.82; χ' Test for overall effect: Z=2 Test for subgroup differences Study or subgroup Asian Grange et al ²³ Wilkinson et al ⁴	0 (P <0.0001) ² =713.86, df =2 8 (P <0.0001) s: χ^2 =1.92, df = TB Events 9 69	27 (<i>P</i> <0.00 =2 (<i>P</i> =0.38 Total 40 104	0001);	1% 3,599 =96% Control Events	38 42	(% 4. 4.	/eight 6) 2 8	Odds M–H, 0.94 (0 5.56 (2	ratio random, 95% Cl 0.33, 2.68) 2.50, 12.35)	Year 1985 2000	-100	Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: t ² =129.43; χ' Test for overall effect: Z=3.94 Total (95% CI) Heterogeneity: t ² =235.82; χ' Test for overall effect: Z=4.24 Test for subgroup differences Study or subgroup Asian Grange et al ²³ Wilkinson et al ⁴² Sasidharan et al ²⁸	0 (P <0.0001) ^{2=713.86, df=2 8 (P<0.0001) s: χ^2=1.92, df= TB Events 9 69 16}	27 (P<0.00 22 (P=0.38 Total 40 104 35	0001); <i>P</i> = 8), <i>P</i> =0% <u>C</u> E 9 1 0	1% 3,599 =96% Control Events	38 42 16	(% 4. 4. 1.	/eight 6) 2 8 4	Odds M–H, 0.94 ((5.56 (2 27.92	ratio random, 95% Cl 1.33, 2.68) 2.50, 12.35) (1.55, 501.86)	Year 1985 2000 2002	-100	Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: t^2 =129.43; χ' Test for overall effect: Z=3.91 Total (95% CI) Heterogeneity: t^2 =235.82; χ' Test for overall effect: Z=4 Test for subgroup differences Study or subgroup Asian Grange et al ²³ Wilkinson et al ⁴⁵ Sasidharan et al ²⁸ Martineau et al ³³ Ho-Pham et al ²⁹	0 (<i>P</i> <0.0001) ² =713.86, <i>df</i> =2 8 (<i>P</i> <0.0001) s: χ ² =1.92, <i>df</i> = TB Events 9 69 16 60 8	27 (<i>P</i> <0.00 2 (<i>P</i> =0.3) Total 40 104 35 84 166	0001); <i>P</i> = 8), <i>P</i> =0% C E 9 1 0 3 4	1% 3,599 =96% Control Events 1	38 42 16 55 219	(% 4. 1. 5. 3.	leight 6) 2 8 4 0 8	Odds M–H, 0.94 ((5.56 (2 27.92 1.94 ((2.72 (ratio random, 95% CI 0.33, 2.68) 2.60, 12.35) (1.55, 501.86) 0.95, 3.95) 0.81, 9.20)	Year 1985 2000 2002 2010 2010	-100	Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: t^2 =129.43; χ' Test for overall effect: Z=3.94 Total (95% CI) Heterogeneity: t^2 =235.82; χ' Test for overall effect: Z=4.21 Test for subgroup differences Study or subgroup Asian Grange et al ²³ Wilkinson et al ⁴⁵ Sasidharan et al ²⁸ Martineau et al ²³ Ho-Pham et al ²² Koo et al ⁴⁷	0 (<i>P</i> <0.0001) ² =713.86, <i>df</i> =2 8 (<i>P</i> <0.0001) s: χ ² =1.92, <i>df</i> = TB Events 9 69 16 60 8 42	27 (P<0.0) 22 (P=0.3) Total 40 104 35 84 166 116	0001); <i>P</i> = 8), <i>P</i> =0% C E 9 1 0 3 4 4 2	1% 3,599 =96% Control Events	38 42 16 55 219 86	(% 4. 1. 5. 3. 5.	leight 6) 2 8 4 0 8 3	Odds M–H, 5.56 (2 27.92 1.94 ((2.72 ((1.47 ((ratio random, 95% Cl 1.33, 2.68) 2.50, 12.35) 1.55, 501.86) 1.95, 3.95) 8.81, 9.20) 3.80, 2.68)	Year 1985 2000 2012 2010 2010 2012	-100	Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: t^2 =129.43; χ' Test for overall effect: Z=3.94 Total (95% CI) Heterogeneity: t^2 =235.82; χ' Test for overall effect: Z=4.21 Test for subgroup differences Study or subgroup Asian Grange et al ²³ Wilkinson et al ⁴⁵ Sasidharan et al ²⁸ Martineau et al ³³ Ho-Pham et al ³² Koo et al ⁴⁷ Kim et al ⁸⁵ Chaudhary et al ³⁹	0 (<i>P</i> <0.0001) ² =713.86, <i>df</i> =2 8 (<i>P</i> <0.0001) s: χ ² =1.92, <i>df</i> = TB Events 9 69 16 60 8 42 73 51	27 (P<0.0) 22 (P=0.3) Total 40 104 35 84 166 116 165 70	0001); <i>P</i> = 8), <i>P</i> =0% C E 9 1 0 3 4 2 2 4 4	1% 3,599 =96% Control Events 1 1 1 1 4 1 9	38 42 16 55 219 86 197 85	(% 4. 1. 5. 3. 5. 5. 5.	leight 6) 2 8 4 0 8 3 4 1	Odds M–H, 0.94 ((5.56 (27.92 1.94 ((2.72 ((1.47 ((6.65 (1.97 (1.97 (ratio random, 95% Cl 1.33, 2.68) 2.50, 12.35) (1.55, 501.86) 0.95, 3.95) 0.81, 9.20) 0.80, 2.68) 3.85, 11.49) 0.00, 3.89)	Year 1985 2000 2012 2010 2012 2013 2013	-100	Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: τ^2 =129.43; χ' Test for overall effect: Z=3.91 Total (95% CI) Heterogeneity: τ^2 =235.82; χ' Test for overall effect: Z=22 Test for subgroup differences Study or subgroup Asian Grange et al ²³ Wilkinson et al ⁴⁵ Sasidharan et al ²⁸ Martineau et al ³³ Ho-Pham et al ⁴² Koo et al ³⁷ Kim et al ⁴⁵ Chaudhary et al ³⁹	0 (P <0.0001) ² =713.86, df =2 8 (P <0.0001) s: χ^2 =1.92, df = TB Events 9 9 69 16 60 8 42 73 51 11	27 (<i>P</i> <0.0) 22 (<i>P</i> =0.3) Total 40 104 35 84 116 165 70 25	0001); <i>P</i> = 8), <i>P</i> =0% C E 9 1 0 3 4 2 2 2 4 0	1% 3,599 =96% Control vents 1 1 4 1 9 9	38 42 16 55 219 86 197 85 25	(% 4. 4. 5. 3. 5. 5. 5. 1.	leight 2 8 4 0 8 3 4 1 4	Odds M–H, 0.94 ((5.56 (2 27.92 1.94 ((2.72 (1.47 ((6.65 (1.97 (40.45	ratio random, 95% Cl 2.50, 12.35 (1.55, 501.86) .95, 3.95) .84, 9.20) .80, 2.68) .85, 11.49) 1.00, 3.89) (.222, 737.97)	Year 1985 2000 2010 2010 2010 2010 2013 2013 2013	-100	Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: τ^2 =129.43; χ' Test for overall effect: Z=3.94 Total (95% CI) Heterogeneity: τ^2 =235.82; χ' Test for overall effect: Z=2 Test for subgroup differences Study or subgroup Asian Grange et al ⁴² Wilkinson et al ⁴³ Sasidharan et al ²⁸ Martineau et al ³² Hoo-Pham et al ³² Koo et al ³⁷ Kim et al ³² Chaudhary et al ³⁶ Hong et al ⁴⁶ Hong et al ⁴⁶	0 (<i>P</i> <0.0001) ² =713.86, <i>df</i> =2 8 (<i>P</i> <0.0001) s: χ ² =1.92, <i>df</i> = TB Events 9 69 16 60 8 42 73 51	27 (P<0.0) 2 (P=0.3) Total 40 104 35 84 166 165 70 25 94 60	0001); <i>P</i> = 8), <i>P</i> =0% C E 9 1 0 3 4 2 2 2 4 0	1% 3,599 =96% Control Events 1 1 1 1 1 9 09	38 42 16 55 219 86 197 85 25 282 118	(% 4. 4. 5. 5. 5. 5. 1. 5. 5. 5. 5.	/eight 6) 2 8 4 0 8 3 4 1 4 1 2	Odds M-H, 5.56 (; 27.92 1.94 ((2.72 () 1.47 () 6.65 (; 1.97 () 40.45 2.64 () 1.22 ()	ratio random, 95% Cl 0.33, 2.68) 2.50, 12.35) 1.55, 501.86) 0.95, 3.95) 3.81, 9.20) 3.80, 2.68) 3.85, 11.49) 1.00, 3.89) (2.22, 737,97) 1.33, 5.22) 1.66, 2.28)	Year 1985 2000 2012 2010 2012 2013 2013	-100	Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: t^2 =129.43; χ' Test for overall effect: Z=3.91 Total (95% CI) Heterogeneity: t^2 =235.82; χ' Test for overall effect: Z=24 Test for subgroup differences Study or subgroup Asian Grange et al ²³ Wilkinson et al ⁴²³ Sasidharan et al ²³ Martineau et al ³³ Ho-Pham et al ²² Koo et al ³⁷ Kim et al ³⁵ Chaudhary et al ³⁹ Joshi et al ⁵⁶ Jubulis et al ⁴⁷ Subtotal (95% CI)	$\begin{array}{c} 0 \ (P{<}0.0001) \\ \end{array} \\ \begin{array}{l} 2{=}713.86, \ df{=}2\\ 8 \ (P{<}0.0001) \\ {\rm s}; \ \chi^{2}{=}1.92, \ df{=} \\ \hline \end{array} \\ \begin{array}{l} {\bf TB} \\ {\bf Events} \\ \hline \\ 9 \\ 69 \\ 16 \\ 60 \\ 8 \\ 42 \\ 73 \\ 51 \\ 11 \\ 83 \\ 33 \\ \end{array} \\ \begin{array}{l} {\rm s}_{3} \\ {\rm s}_{3} \\ {\rm s}_{3} \\ \end{array} \end{array}$	27 (P<0.00 22 (P=0.38 Total 40 104 35 84 166 116 165 70 25 94	0001); <i>P</i> = 8), <i>P</i> =0% C E 9 1 0 3 4 4 2 2 4 4 0 2 2 5	1% 3,599 =96% Control ivents 1 1 1 1 9 9 9 9	38 42 16 55 219 86 197 85 25 282	(% 4. 4. 5. 3. 5. 5. 5. 1. 5.	/eight 6) 2 8 4 0 8 3 4 1 4 1 2	Odds M-H, 5.56 (; 27.92 1.94 ((2.72 () 1.47 () 6.65 (; 1.97 () 40.45 2.64 () 1.22 ()	ratio random, 95% Cl 1.33, 2.68) 2.50, 12.35) (1.55, 501.86) 9.95, 3.95) 0.81, 9.20) 0.80, 2.68) 0.85, 11.49) 1.00, 3.89) (2.22, 737.97) 1.33, 5.22)	Year 1985 2000 2010 2010 2012 2013 2013 2013 2014	-100	Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: τ^2 =129.43; χ' Test for overall effect: Z=3.94 Total (95% CI) Heterogeneity: τ^2 =235.82; χ' Test for overall effect: Z=2 Test for subgroup differences Study or subgroup Asian Grange et al ⁴² Wilkinson et al ⁴³ Sasidharan et al ²⁸ Martineau et al ³² Hoo-Pham et al ³² Koo et al ³⁷ Kim et al ³² Chaudhary et al ³⁶ Hong et al ⁴⁶ Hong et al ⁴⁶	0 (P <0.0001) ² =713.86, df =2 8 (P <0.0001) s: χ^2 =1.92, df = TB Events 9 69 16 60 8 42 73 51 11 83 33 455 50.04, df =10 (l	27 (P<0.0) 22 (P=0.3) Total 40 104 35 84 166 165 70 25 94 60 959	0001); <i>P</i> = 8), <i>P</i> =0% C E 9 1 0 3 4 2 2 2 4 0 5 5	3,599 =96% Control Events 1 1 1 4 1 9 9 9 9 9 9	38 42 16 55 219 86 197 85 25 282 118	(% 4. 4. 5. 5. 5. 5. 1. 5. 5. 5. 5.	/eight 6) 2 8 4 0 8 3 4 1 4 1 2	Odds M-H, 5.56 (; 27.92 1.94 ((2.72 () 1.47 () 6.65 (; 1.97 () 40.45 2.64 () 1.22 ()	ratio random, 95% Cl 0.33, 2.68) 2.50, 12.35) 1.55, 501.86) 0.95, 3.95) 3.81, 9.20) 3.80, 2.68) 3.85, 11.49) 1.00, 3.89) (2.22, 737,97) 1.33, 5.22) 1.66, 2.28)	Year 1985 2000 2010 2010 2012 2013 2013 2013 2014	_100	Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: τ^2 =129.43; χ' Test for overall effect: Z=3.91 Heterogeneity: τ^2 =235.82; χ' Test for overall effect: Z=3.72 Test for subgroup differences Study or subgroup Asian Grange et all ²³ Wilkinson et all ⁴³ Sasidharan et al ²² Martineau et all ³³ Ho-Pham et all ³² Koo et all ⁴⁷ Kim et all ⁹⁵ Chaudhary et all ⁹⁵ Joshi et all ⁶⁵ Jobshi et all ⁶⁵	$0 (P<0.0001)$ $^{2}=713.86, df=2$ $8 (P<0.0001)$ s: $\chi^{2}=1.92, df=$ TB Events 9 69 16 60 8 42 73 51 11 83 33 455 55.04, df=10 (l 6 (P<0.0001))	27 (P<0.00 22 (P=0.34 Total 40 104 35 84 116 165 70 25 94 60 959 P=0.0001	00001); <i>P</i> = 8), <i>P</i> =0% C E 9 1 0 3 3 4 4 2 2 5 5 5); <i>P</i> =71%	1% 3,599 =96% Control vents 1 1 1 1 1 9 09 9 17	38 42 16 55 219 86 197 85 25 282 118 1,163	(% 4. 4. 5. 3. 5. 5. 5. 5. 5. 46	leight 6) 2 8 4 0 8 3 4 1 1 4 1 2 5.7	Odds M-H, 0.94 (l 5.56 (c) 27.92 1.94 (l 2.72 (l 1.47 (l 6.65 (c) 1.97 (40.45 2.64 (c) 1.22 (l 2.62 (ratio random, 95% Cl 1.33, 2.68) 2.50, 12.35) 1.155, 501.86) 1.95, 3.95) 8.81, 9.20) 3.85, 11.49) 1.00, 3.89) (2.22, 737, 97) 1.33, 5.22) 0.66, 2.28) 1.63, 4.23)	Year 1985 2000 2010 2010 2012 2013 2013 2014 2014	-100	Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: r^2 =129.43; χ' Test for overall effect: Z=3.91 Total (95% CI) Heterogeneity: r^2 =235.82; χ' Test for overall effect: Z=22 Test for subgroup differences Study or subgroup Asian Grange et al ²² Wilkinson et al ²³ Wilkinson et al ²³ Martineau et al ²³ Martineau et al ²³ Martineau et al ²³ Koo et al ²⁷ Kim et al ²⁶ Chaudhary et al ³⁹ Hong et al ⁴⁶ Subtotal (95% CI) Total events Heterogeneity: r^2 =0.41; χ^2 =5 Test for overall effect: Z=3.90 African Wejse et al ⁶	$0 (P<0.0001)$ $2=713.86, df=2$ $R(P<0.0001)$ s: $\chi^2=1.92, df=$ TB Events 9 69 69 16 60 8 42 73 51 11 83 33 455 51.04, df=10 (l 6 (P<0.0001) 31	27 (P<0.00 2 (P=0.38 Total 40 104 35 84 166 165 70 25 94 60 959 P=0.0001] 362	0001); <i>P</i> = 8), <i>P</i> =0% CE 9 1 0 3 4 2 2 4 4 0 2 2 5 5); <i>P</i> =71% 6	1% 3,599 =96% Control vents 1 1 1 1 1 9 9 9 1 17 5	38 42 16 55 219 86 197 85 25 282 118 1,163	(% 4. 4. 5. 5. 5. 5. 5. 5. 46	feight (6) 2 8 4 4 0 8 3 4 1 4 1 2 5.7 6	Odds M–H, 5.56 (; 27.92 1.94 (() 2.72 () 1.97 () 40.45 (; 1.97 () 40.45 () 1.22 () 2.62 ()	ratio random, 95% CI 0.33, 2.68) 2.50, 12.35; (1.55, 501.86) 0.95, 3.95) 3.81, 9.20) 3.80, 2.68) 3.85, 11.49) 1.00, 3.89) (2.22, 737, 97) 1.33, 5.22) 0.66, 2.28) 1.83, 4.23)	Year 1985 2000 2010 2010 2013 2013 2013 2014 2014		Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: r^2 =129.43; χ' Test for overall effect: Z=3.91 Total (95% CI) Heterogeneity: r^2 =235.82; χ' Test for overall effect: Z=22 Test for subgroup differences Study or subgroup Asian Grange et al ²² Wilkinson et al ⁴² Sasidharan et al ²⁸ Martineau et al ³³ Ho-Pham et al ⁴² Koo et al ³⁷ Kim et al ⁴⁵ Chaudhary et al ³⁹ Hong et al ⁴⁶ Hong et al ⁴⁶ Hong et al ⁴⁶ Subulis et al⁴⁷ Subtotal (95% CI) Total events Heterogeneity: r^2 =0.41; χ^2 =3 For overall effect: Z=3.90 African Wejse et al ⁸ Gibney et al ⁸	$\begin{array}{c} 0 \ (P{<}0.0001) \\ \\ 2^{=}713.86, \ df{=}2 \\ \\ 8 \ (P{<}0.0001) \\ \text{s: } \chi^{2}{=}1.92, \ df{=} \\ \hline \\ \textbf{TB} \\ \textbf{Events} \\ \hline \\ 9 \\ 69 \\ 16 \\ 60 \\ 8 \\ 42 \\ 73 \\ 51 \\ 11 \\ 83 \\ 33 \\ 455 \\ 35.04, \ df{=}10 \ (l \\ 6 \ (P{<}0.0001) \\ \hline \\ 31 \\ 31 \\ 6 \end{array}$	27 (P<0.00 2 (P=0.38 Total 40 104 35 84 166 165 70 25 94 60 959 P=0.0001) 362 40 50	0001); <i>P</i> = 8), <i>P</i> =0% C E 9 1 0 3 3 4 4 2 2 2 5 5 5 5); <i>P</i> =71% 6 2 5 5	1% 3,599 =96% Control vents 1 1 1 1 4 1 9 9 9 17 5 9	38 42 16 55 219 86 197 85 25 282 118 1,163 494 415 50	(9 4. 4. 5. 5. 5. 5. 5. 4(4. 3.	leight 6) 2 2 8 4 1 4 1 2 2 3 3 4 1 2 2 3 3 4 1 2 2 8 3 3 4 5 7 6 7 7	Odds M–H, 0.94 ((2.7.92 1.94 ((2.7.2 () 1.97 () 1.47 () 40.45 2.64 () 1.22 () 2.62 () 0.62 ((10.21 () 1.23 ()	ratio random, 95% CI 0.33, 2.68) 2.50, 12.35; (1.55, 501.86) 0.95, 3.95) 3.81, 9.20) 3.80, 2.68; 3.85, 11.49) 1.00, 3.89; (2.22, 737, 97) 1.33, 5.22; D.66, 2.28) 1.63, 4.23) 0.66, 2.28; 1.63, 4.23)	Year 1985 2000 2002 2010 2012 2013 2014 2014 2014 2007 2008 2011		Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: τ^2 =129.43; χ^2 Test for overall effect: Z=3.91 Heterogeneity: τ^2 =235.82; χ^2 Test for overall effect: Z=3.91 East for overall effect: Z=3.94 Subgroup differences Study or subgroup differences Wilkinson et al ⁴² Sasidharan et al ²³ Wilkinson et al ⁴³ Martineau et al ³³ Ho-Pham et al ²² Koo et al ³⁷ Kim et al ⁸⁶ Chaudhary et al ³⁹ Jobbi et al ⁸⁶ Hong et al ⁸⁶ Jubuis et al ⁸⁶ Jubuis et al ⁸⁶ Subtotal (95% CI) Total events Heterogeneity: τ^2 =0.41; χ^2 =5 Test for overall effect: Z=3.96 African Weijse et al ⁸⁶ Gibney et al ²⁶ Nansera et al ⁴⁴ Martineau et al ³²	$0 (P<0.0001)$ $2=713.86, df=2$ $8 (P<0.0001)$ $8 (P<0.0001)$ $x^{2}=1.92, df=2$ TB Events 9 69 16 60 8 42 73 51 11 83 35 51 11 83 35 55 55 4, df=10 (f 6 (P<0.0001) 31 6 155	27 (P<0.00 22 (P=0.34 Total 40 104 35 84 166 165 70 25 94 60 959 P=0.0001] 362 40 50 192	00001); <i>P</i> =0% 8), <i>P</i> =0% C E E E C C C C C C C C	1% 3,599 =96% Control Vents 1 1 1 4 1 9 9 9 17 5 9 7	38 42 16 55 219 86 197 85 25 285 285 218 1,163 494 115 50 178	(9 4. 4. 1. 5. 5. 5. 5. 5. 4. 4. 3. 5. 5. 4. 4. 5. 4. 4. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	leight 6) 2 8 4 4 0 8 3 4 1 1 2 3.7 6 6	Odds M-H, 0.94 ((5.56 () 27.92 1.94 ((2.72 () 1.47 ((6.65 () 1.97 () 1.47 ((40.45 2.64 () 1.22 () 2.62 () 0.62 ((10.21 1.23 () 5.49 () 5.49 ()	ratio random, 95% Cl 1.33, 2.68) 2.50, 12.35) (1.55, 501.86) 0.95, 3.95) 0.80, 2.68) 8.85, 11.49) 1.00, 3.89) (2.22, 737.97) 1.33, 5.22) 1.66, 2.28) 1.63, 4.23) 0.39, 0.97) (4.35, 23.97) 0.35, 4.32) 3.45, 8.75)	Year 1985 2000 2010 2010 2013 2013 2013 2014 2014 2014 2014		Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: τ^2 =129.43; χ^2 Test for overall effect: Z=3.91 Heterogeneity: τ^2 =235.82; χ^2 Test for overall effect: Z=3.91 East for overall effect: Z=2 Test for subgroup differences Study or subgroup Asian Grange et al ²³ Wilkinson et al ⁴² Sasidharan et al ²³ Ho-Pham et al ²² Koo et al ³⁷ Kim et al ⁸⁶ Chaudhary et al ³⁹ Jubuis et al ⁴⁶ Jubuis et al ⁴⁶ Jubuis et al ⁴⁶ Jubuis et al ⁴⁶ Subtotal (95% CI) Total events Heterogeneity: τ^2 =0.41; χ^2 =3 African Weijse et al ⁵ Gibney et al ²⁵ Nansera et al ⁴⁶ Steenhoff et al ⁴¹⁵	0 (P<0.0001) $2=713.86, df=2$ $8 (P<0.0001)$ $8 (P<0.0001)$ $8 (P<0.0001)$ $8 (P<0.0001)$ 9 69 16 60 8 42 73 51 11 83 33 455 55 55 15 19	27 (P<0.00 22 (P=0.34 Total 40 104 35 84 166 165 165 94 60 959 P=0.0001) 362 40 50 192 19 119	0001); ℓ= 8), ℓ=0%	1% 3,599 =96% Control Vents 1 1 1 1 4 1 9 9 9 17 5 9 7 5	38 42 16 55 219 86 197 85 282 118 1,163 494 115 50 178 19 43	(9 4. 4. 1. 5. 5. 5. 5. 5. 5. 46 4. 3. 5. 4. 3. 4. 4. 4. 4.	eight 2 8 4 0 8 3 4 4 1 2 5.7 6 7 7 6 1 2	Odds M-H, 0.94 ((5.56 () 27.92 1.94 ((2.72 () 1.47 ((6.65 () 1.97 () 1.97 () 2.64 () 1.92 () 2.64 () 1.22 ((2.62 () 1.02 () 1.23 () 5.49 () 5.49 () 1.24 () 1.24 ()	ratio random, 95% Cl 1.33, 2.68) 2.60, 12.35) (1.55, 501,86) 0.95, 3.95) 0.81, 9.20) 0.80, 2.68) 0.82, 2.03 0.82, 13.49) (2.22, 737,97) 1.63, 2.22) 0.66, 2.28) 1.63, 4.23) 0.39, 0.97) (4.35, 23.97) 0.35, 4.32) 3.45, 8.75) 0.21, 4.76) 0.50, 4.14)	Year 1985 2000 2010 2010 2010 2013 2013 2013 2014 2014 2014 2014 2014 2014 2012 2007 2008 2011 2012 2012 2012 2012 2012 2012		Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: r^2 =129.43; χ' Test for overall effect: Z=3.94 Total (95% CI) Heterogeneity: r^2 =235.82; χ' Test for overall effect: Z=3 Test for subgroup differences Study or subgroup Asian Grange et al ²³ Wilkinson et al ⁴³ Sasidharan et al ²⁹ Martineau et al ³² Hong et al ⁴² Chaudhary et al ³² Hong et al ⁴² Chaudhary et al ³² Hong et al ⁴² Joshi et al ⁴⁵ Hong et al ⁴⁶ Hong et al ⁴⁶ Hong et al ⁴⁶ Subtotal (95% CI) Total events Heterogeneity: r^2 =0.41; χ^2 =3 Gibney et al ⁸ Mansera et al ⁴⁴ Martineau et al ⁴⁵ Mansera et al ⁴⁴	$0 (P<0.0001)$ $^{2}=713.86, df=2$ $FB = 0001$ $S: \chi^{2}=1.92, df=$ $\frac{FB}{69}$ 16 60 8 42 73 51 11 83 333 455 $35.04, df=10 (f$ $6 (P<0.0001)$ 31 31 6 155 15 19 68	27 (P<0.00 2 (P=0.34 Total 40 104 35 84 166 1165 166 1165 94 66 959 959 P=0.0001 362 40 50 199 19 119 161	00001); P= 8), P=0% 9 9 1 0 0 3 3 4 4 2 2 2 2 2 4 4 0 0 2 2 5 7 7 1 5 2 2	3,599 =96% control events 1 1 1 1 1 9 9 17 5 5 6	38 42 16 55 219 86 197 85 25 282 118 1,163 494 115 50 178 19 43 157	(9 4. 4. 1. 5. 5. 5. 5. 5. 5. 4. 3. 5. 5. 4. 3. 4. 5. 5. 4. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	Feight (6) 2 8 8 4 4 0 8 3 4 4 1 1 2 5.7 7 6 6 7 7 7 6 1 2 4	Odds M-H, 0.94 ((5.56 (27.92 2.72 (0 1.94 ((1.27 ((1.27 ((1.27 ((1.27 ((1.22 ((1.23 ((ratio random, 95% CI 0.33, 2.68) 2.60, 12.35) (1.55, 501.86) 0.95, 3.95) 3.81, 9.20) 3.80, 2.68) 3.85, 11.49) 1.00, 3.89) (2.22, 737, 97) 1.33, 5.22) 0.66, 2.28) 1.63, 4.23) 0.66, 2.28) 1.63, 4.23) 0.39, 0.97) (4.35, 23.97) 0.35, 4.32) 3.55, 4.32) 3.55, 4.32) 3.55, 4.32) 3.54, 4.76) 3.50, 4.14) 2.18, 6.22)	Year 1985 20000 2010 2010 2013 2013 2013 2014 2014 2014 2007 2008 2007 2008 2011 2011 2012 2013		Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: r^2 =129.43; χ^2 Test for overall effect: Z=3.91 Total (95% CI) Heterogeneity: r^2 =235.82; χ^2 Test for overall effect: Z=3.91 Test for overall effect: Z=2 Test for subgroup differences Study or subgroup Asian Grange et al ²³ Wilkinson et al ⁴² Sasidharan et al ²³ Martineau et al ³⁴ Ho-Pham et al ²² Koo et al ³⁷ Kim et al ³⁶ Chaudhary et al ³⁹ Hong et al ⁴⁶ Subtotal (95% CI) Total events Heterogeneity: r^2 =0.41; χ^2 =7 Test for overall effect: Z=3.91 Arrican Wejse et al ⁹ Gibney et al ⁹ Steenhoff et al ¹¹⁵ Steenhoff et al ¹¹⁵ Steenhoff et al ¹¹⁵ Steenhoff et al ¹¹⁵	0 (P<0.0001) $2=713.86, df=2$ $8 (P<0.0001)$ $8 (P<0.0001)$ $8 (P<0.0001)$ $8 (P<0.0001)$ 9 69 16 60 8 42 73 51 11 83 33 455 55 55 15 19	27 (P<0.00 22 (P=0.34 Total 40 104 35 84 166 165 165 94 60 959 P=0.0001) 362 40 50 192 19 119	00001); P=0% 8), P=0% C E 9 9 1 0 3 3 4 4 2 2 2 4 4 4 2 5 5 5 5 5 5 5 5 5 5 5 5 5	3,599 =96% control events 1 1 1 1 1 9 9 17 5 5 6	38 42 16 55 219 86 197 85 282 118 1,163 494 115 50 178 19 43	(% 4.4. 1. 5. 5. 5. 5. 5. 5. 4. 4. 5. 5. 4. 5. 5. 4. 5. 5. 4. 5. 5. 4. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	Feight (6) 2 8 8 4 4 0 8 3 4 4 1 1 2 5.7 7 6 6 7 7 7 6 1 2 4	Odds M-H, 0.94 ((5.56 () 27.92 1.94 ((2.72 () 2.72 () 1.47 ((6.65 () 1.97 () 1.97 () 2.64 () 1.92 () 2.64 () 1.22 ((2.62 () 0.62 ((10.21 1.23 () 5.49 () 5.49 () 1.04 () 1.94 () 0.54 () 0.55 () 0.54 () 0.54 () 0.54 () 0.55 () 0.54 () 0.54 () 0.55 () 0.54 () 0.54 () 0.55 () 0.54 () 0.54 () 0.54 () 0.55 ()0	ratio random, 95% Cl 1.33, 2.68) 2.60, 12.35) (1.55, 501,86) 0.95, 3.95) 0.81, 9.20) 0.80, 2.68) 0.82, 2.03 0.82, 13.49) (2.22, 737,97) 1.63, 2.22) 0.66, 2.28) 1.63, 4.23) 0.39, 0.97) (4.35, 23.97) 0.35, 4.32) 3.45, 8.75) 0.21, 4.76) 0.50, 4.14)	Year 1985 2000 2010 2010 2010 2013 2013 2013 2014 2014 2014 2014 2014 2014 2012 2007 2008 2011 2012 2012 2012 2012 2012 2012		Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: τ^2 =129.43; χ' Test for overall effect: Z=3.91 Heterogeneity: τ^2 =235.82; χ' Test for overall effect: Z=3.94 Total (95% CI) Test for overall effect: Z=3.94 Study or subgroup differences Study or subgroup Asian Grange et al ²³ Wilkinson et al ⁴⁸ Sasidharan et al ²⁸ Martineau et al ²³ Ho-Pham et al ²² Koo et al ²⁷ Kim et al ⁸⁶ Hong et al ⁸⁶ Hong et al ⁸⁶ Jobalis et al ⁸⁶ Hotarogeneity: τ^2 =0.41; χ^2 =3 Test for overall effect: Z=3.96 African Weise et al ⁸⁶ Gibney et al ²⁹ Nansera et al ¹⁴⁶ Steenhoff et al ¹¹¹ Conesa-Botella et al ¹²⁵ Mastineau et al ⁸⁶ Steenhoff et al ¹¹¹ Conesa-Botella et al ¹²⁵ Mastineau et al ⁸⁶ Steenhoff et al ¹¹¹ Conesa-Botella et al ¹²⁵ Mastineau et events Heterogeneity: τ^2 =1.23; χ^2 =5	$\begin{array}{c} 0 \ (P{<}0.0001) \\ \\ 2=713.86, \ df{=}2 \\ \\ 8 \ (P{<}0.0001) \\ \\ \text{s: } \chi^{2}=1.92, \ df{=} \\ \hline \\ \textbf{B} \\ \textbf{Events} \\ \hline \\ \textbf{9} \\ 69 \\ 16 \\ 60 \\ 8 \\ 42 \\ 73 \\ 51 \\ 11 \\ 83 \\ 33 \\ 455 \\ 55 \\ 15 \\ 15 \\ 15 \\ 15 \\ 15 \\ 1$	27 (P<0.00 2 (P=0.38 Total 40 104 35 84 166 165 70 25 94 60 959 P=0.0001) 362 40 50 192 19 119 161 1,223 2,166	0001); P= B), P=0% C E 9 9 1 0 3 3 4 4 2 2 5 5 5 7 7 7 7 7 7 7 7 2 2 2 2 2 2 2 2 2 2 2 2 2	3,599 -96% control vents 1 1 1 1 1 1 9 9 9 9 1 7 5 5 6 5 3 7	38 42 16 55 219 86 197 85 25 282 118 1,163 494 115 50 178 19 43 157	(% 4.4. 1. 5. 5. 5. 5. 5. 5. 4. 4. 5. 5. 4. 5. 5. 4. 5. 5. 4. 5. 5. 4. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	feight 2 8 4 0 3 4 1 2 6 7 6 7 6 1 2 4 2	Odds M-H, 0.94 ((5.56 () 27.92 1.94 ((2.72 () 2.72 () 1.47 ((6.65 () 1.97 () 1.97 () 2.64 () 1.92 () 2.64 () 1.22 ((2.62 () 0.62 ((10.21 1.23 () 5.49 () 5.49 () 1.04 () 1.94 () 0.54 () 0.55 () 0.54 () 0.54 () 0.54 () 0.55 () 0.54 () 0.54 () 0.55 () 0.54 () 0.54 () 0.55 () 0.54 () 0.54 () 0.54 () 0.55 ()0	ratio random, 95% Cl 1.33, 2.68) 2.60, 12.35) (1.55, 501,86) 9.85, 395) 3.81, 9.20) 9.80, 2.68) 3.85, 11.49) (1.00, 3.89) (2.22, 737,97) 1.63, 2.22) 1.66, 2.28) 1.63, 4.23) 1.63, 4.23) 1.63, 4.23) 1.63, 4.23) 1.64, 5, 23,97) 1.35, 4.23) 4.54, 8.75) 1.21, 4.76) 1.50, 4.14) 2.18, 6.22) 3.51, 1.08)	Year 1985 20000 2010 2010 2013 2013 2013 2014 2014 2014 2007 2008 2007 2008 2011 2011 2012 2013		Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: r^2 =129.43; χ' Test for overall effect: Z=3.91 Heterogeneity: r^2 =235.82; χ' Test for overall effect: Z=3.91 Total (95% CI) Test for overall effect: Z=2 Test for subgroup differences Study or subgroup Asian Grange et al ²³ Wilkinson et al ⁴² Sasidharan et al ²³ Ho-Pham et al ²³ Koo et al ⁴⁷ Sabidharan et al ²³ Koo et al ⁴⁷ Joshi et al ⁴⁵ Hong et al ⁴⁵ Hong et al ⁴⁵ Jubulis et al ⁴⁵ Subtotal (95% CI) Total events Heterogeneity: r^2 =0.41; χ^2 =5 Test for overall effect: Z=3.91 African Weise et al ⁸⁵ Subtotal (95% CI) Total events Heterogeneity: r^2 =1.23; χ^2 =5 Total events Heterogeneity: r^2 =1.23; χ^2 =5 Test for overall effect: Z=1.51	$\begin{array}{c} 0 \ (P{<}0.0001) \\ \\ 2=713.86, \ df{=}2 \\ \\ 8 \ (P{<}0.0001) \\ \\ \text{s: } \chi^{2}=1.92, \ df{=} \\ \hline \\ \textbf{B} \\ \textbf{Events} \\ \hline \\ \textbf{9} \\ 69 \\ 16 \\ 60 \\ 8 \\ 42 \\ 73 \\ 51 \\ 11 \\ 83 \\ 33 \\ 455 \\ 55 \\ 15 \\ 15 \\ 15 \\ 15 \\ 15 \\ 1$	27 (P<0.00 2 (P=0.38 Total 40 104 35 84 166 165 70 25 94 60 959 P=0.0001) 362 40 50 192 19 119 161 1,223 2,166	0001); P= B), P=0% C E 9 9 1 0 3 3 4 4 2 2 5 5 5 7 7 7 7 7 7 7 7 2 2 2 2 2 2 2 2 2 2 2 2 2	3,599 -96% control vents 1 1 1 1 1 1 9 9 9 9 1 7 5 5 6 5 3 7	38 42 16 55 219 86 197 85 25 282 118 1,163 494 115 50 178 19 43 157	(% 4.4. 1. 5. 5. 5. 5. 5. 5. 4. 4. 5. 5. 4. 5. 5. 4. 5. 5. 4. 5. 5. 4. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	feight 2 8 4 0 3 4 1 2 6 7 6 7 6 1 2 4 2	Odds M-H, 0.94 ((5.56 () 27.92 1.94 ((2.72 () 2.72 () 1.47 ((6.65 () 1.97 () 1.97 () 2.64 () 1.92 () 2.64 () 1.22 ((2.62 () 0.62 ((10.21 1.23 () 5.49 () 5.49 () 1.04 () 1.94 () 0.54 () 0.55 () 0.54 () 0.54 () 0.54 () 0.55 () 0.54 () 0.54 () 0.55 () 0.54 () 0.54 () 0.55 () 0.54 () 0.54 () 0.54 () 0.55 ()0	ratio random, 95% Cl 1.33, 2.68) 2.60, 12.35) (1.55, 501,86) 9.85, 395) 3.81, 9.20) 9.80, 2.68) 3.85, 11.49) (1.00, 3.89) (2.22, 737,97) 1.63, 2.22) 1.66, 2.28) 1.63, 4.23) 1.63, 4.23) 1.63, 4.23) 1.63, 4.23) 1.64, 5, 23,97) 1.35, 4.23) 4.54, 8.75) 1.21, 4.76) 1.50, 4.14) 2.18, 6.22) 3.51, 1.08)	Year 1985 20000 2010 2010 2013 2013 2013 2014 2014 2014 2007 2008 2007 2008 2011 2011 2012 2013		Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: $r^2=129.43$; χ' Test for overall effect: Z=3.91 Heterogeneity: $r^2=235.82$; χ' Test for overall effect: Z=3.91 Total (95% CI) Test for overall effect: Z=2 Test for subgroup differences Study or subgroup Asian Grange et al ²³ Wilkinson et al ⁴⁵ Sasidharan et al ²² Martineau et al ²³ Ho-Pham et al ²² Kim et al ²⁵ Chaudhary et al ²⁹ Joshi et al ⁴⁵ Hong et al ⁴⁷ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=5$ Test for overall effect: Z=3.91 African Weise et al ⁸⁵ Steenhoff et al ¹¹⁷ Conesa-Botella et al ^{12,51} Mastala et al ⁴⁵ Steenhoff et al ¹¹⁷ Conesa-Botella et al ^{12,51} Mastala et al ⁴⁵ Steenhoff et al ¹¹⁷ Friis et al ⁴⁵ Subtotal (95% CI) Total events Heterogeneity: $r^2=1.23$; $\chi^2=5$ Test for overall effect: Z=1.51 Ethnicity unspecified	$\begin{array}{c} 0 \ (P{<}0.0001) \\ \\ 2=713.86, \ df{=}2 \\ \\ 8 \ (P{<}0.0001) \\ \\ \text{s: } \chi^{2}=1.92, \ df{=} \\ \hline \\ \textbf{B} \\ \textbf{Events} \\ \hline \\ \textbf{9} \\ 69 \\ 16 \\ 60 \\ 8 \\ 42 \\ 73 \\ 51 \\ 11 \\ 83 \\ 33 \\ 455 \\ 55 \\ 15 \\ 15 \\ 15 \\ 15 \\ 15 \\ 1$	27 (P<0.00 2 (P=0.38 Total 40 104 35 84 166 165 70 25 94 60 959 P=0.0001) 362 40 50 192 19 119 161 1,223 2,166	0001); P= B), P=0% C E 9 9 1 0 3 3 4 4 2 2 5 5 5 7 7 7 7 7 7 7 7 2 2 2 2 2 2 2 2 2 2 2 2 2	3,599 -96% control vents 1 1 1 1 1 9 9 9 1 7 5 5 6 5 3 7	38 42 16 55 219 86 197 85 25 282 118 1,163 494 115 50 178 19 43 157	(9 4. 4. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	feight 2 2 8 4 0 3 3 4 1 1 1 2 7 6 7 7 6 1 2 2 4 4 4 1 2 2 4 2 4	Odds M-H, 0.94 ((5.56 (27.92 2.72 (1.94 () 2.72 () 1.94 () 1.97 (40.45 (1.97 () 40.45 (1.97 () 1.97 () 2.62 () 0.62 ((10.21 () 1.23 ()	ratio random, 95% CI 0.33, 2.68) 2.50, 12.35; (1.55, 501.86) 0.95, 3.95; 0.80, 2.68; 0.80, 2.68; 0.80, 2.68; 0.80, 2.68; 0.85, 11.49; 1.00, 3.89; 0.22, 737,977; 1.33, 5.22; 0.66, 2.28; 1.83, 4.23; 0.66, 2.28; 1.83, 4.23; 0.39, 0.977; 0.435, 2.23,977; 0.35, 4.32; 0.35, 4.32; 0.35, 4.32; 0.35, 4.32; 0.35, 4.32; 0.34, 1.06; 0.50, 4.14; 0.51, 4.16; 0.52, 4.33; 0.52, 4.33; 0.52, 4.33; 0.52, 4.33; 0.53, 4.55; 0.54, 4.55; 0.54, 4.16; 0.55, 4.16; 0.55, 4.16; 0.55, 4.16; 0.55, 4.16; 0.56, 4	Year 1985 20000 2010 2010 2013 2013 2013 2014 2014 2014 2007 2008 2007 2008 2011 2011 2012 2013		Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: r^2 =129.43; χ' Test for overall effect: Z=3.91 Heterogeneity: r^2 =235.82; χ' Test for overall effect: Z=3.91 East for overall effect: Z=3.91 Total (95% CI) Test for overall effect: Z=3.91 Asian Grange et al ⁴² Wilkinson et al ⁴² Sasidharan et al ²³ Martineau et al ³³ Hoo-Pham et al ⁴² Koo et al ⁴⁷ Subtotal (95% CI) Total events Heterogeneity: r^2 =0.41; χ^2 =2 Test for overall effect: Z=3.91 African Wastale et al ⁴³ Steenhoff et al ⁴³ Friise et al ⁴³ Subtotal (95% CI) Total events Heterogeneity: r^2 =1.23; χ^2 =5 Test for overall effect: Z=1.23 Ubtata et al ⁴⁴ Martineau et al ⁴³ Friise et al ⁴⁵ Subtotal (95% CI) Total events Heterogeneity: r^2 =1.23; χ^2 =5 Test for overall effect: Z=1.25 Ethnicity unspecified Sita-Lumsden et al ⁴⁶	$\begin{array}{c} 0 \ (P<0.0001) \\ \hline \\ 2^{2}=713.86, \ df=2 \\ 8 \ (P<0.0001) \\ \text{s: } \chi^{2}=1.92, \ df= \\ \hline \\ $	27 (P<0.00 2 (P=0.38 Total 40 104 35 84 166 165 70 25 94 60 959 P=0.0001) 362 40 50 19 119 161 1,223 2,166 <0.00001) 178 72	0001); P= B), P=0% C E 9 9 1 0 3 3 4 4 2 2 5 5 5 7 7 1 5 5 7 7 1 5 5 7 7 1 5 5 7 1 5 5 7 1 5 5 7 1 5 7 1 5 7 1 5 7 1 5 7 1 5 7 7 7 7 7 7 7 7 7 7 7 7 7	3,599 96% Control vents 1 1 1 1 4 1 9 9 9 17 5 6 5 37 3	38 42 16 55 219 86 197 85 25 282 282 118 1,163 494 115 50 178 494 157 157 347 1,403	(१) 4. 4. 4. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	feight 2 2 8 4 0 3 3 4 1 1 1 2 7 6 7 7 6 1 2 2 4 2 7 6 7 7 6 1 2 2 4 2 2 0 2	Odds M-H, 0.94 ((5.56 (27.92 2.72 (1.94 () 2.72 () 1.97 () 40.45 (2.64 () 1.22 () 2.62 () 0.62 ((10.21 1.23 () 1.03 () 1.04 () 1.04 () 1.04 () 1.04 () 1.04 () 1.05 () 1.	ratio random, 95% CI 0.33, 2.68) 2.50, 12.35; (1.55, 501.86) 0.95, 3.95) 3.81, 9.20) 3.80, 2.68) 3.85, 11.49) 1.00, 3.89) (2.22, 737, 977) 1.33, 5.22) 0.62, 2.28) 1.83, 4.23) 0.39, 0.97) (4.35, 22.397) 0.35, 4.32) 3.45, 8.75) 0.35, 4.32) 3.45, 8.75) 0.21, 4.76) 0.50, 4.14) 2.14, 4.76) 0.50, 4.14) 2.14, 10.8) 0.39, 0.97) (1.25, 82.30)	Year 1985 2000 2002 2010 2013 2013 2013 2014 2014 2014 2014 2017 2007 2007 2013 2013 2013 2013 2013		Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: $r^2=129.43$; χ' Test for overall effect: Z=3.91 Heterogeneity: $r^2=235.82$; χ' Test for overall effect: Z=3.91 Total (95% CI) Test for overall effect: Z=23 Test for subgroup differences Study or subgroup Asian Grange et al ²³ Wilkinson et al ⁴⁵ Sasidharan et al ²² Martineau et al ³³ Ho-Pham et al ³² Kim et al ³⁵ Joshi et al ⁴⁵ Joshi et al ⁴⁵ Joshi et al ⁴⁵ Joshi et al ⁴⁵ Joshi et al ⁴⁵ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=5$ Test for overall effect: Z=3.91 African Weise et al ⁸⁵ Steenhoff et al ¹¹⁰ Conesa-Botella et al ^{12.51} Mastala et al ⁴⁵ Steenhoff et al ¹¹¹ Total events Heterogeneity: $r^2=1.23$; $\chi^2=5$ Test for overall effect: Z=1.51 Ethnicity unspecified Sita-Lumsden et al ¹²⁰ Nielsen et al ¹²⁶	$\begin{array}{c} 0 \ (P{<}0.0001) \\ \\ 2^{2}=713.86, \ df{=}2 \\ 8 \ (P{<}0.0001) \\ \text{s: } \ \chi^{2}=1.92, \ df{=} \\ \hline \mathbf{TB} \\ \mathbf{Events} \\ \hline 9 \\ 69 \\ 16 \\ 60 \\ 60 \\ 60 \\ 60 \\ 60 \\ 82 \\ 73 \\ 51 \\ 11 \\ 83 \\ 33 \\ 455 \\ 55 \\ 15 \\ 16 \\ (P{<}0.0001) \\ 31 \\ 6 \\ (P{<}0.0001) \\ 31 \\ 6 \\ 155 \\ 15 \\ 19 \\ 68 \\ 31 \\ 356 \\ 30.11, \ df{=}7 \ (P{-} \\ 0 \ (P{=}0.13) \\ 167 \\ 9 \\ 9 \end{array}$	27 (P<0.01 22 (P=0.34 40 104 35 84 166 1165 70 959 P=0.0001; 362 40 50 199 199 199 191 1,223 2,166 <0.00001) 178 72 11	0001); P= C E 9 9 1 0 3 3 4 4 2 2 2 4 4 4 2 5 5 5 2 2 2 2 2 2 2 2 2 2 2 2 2	3,599 =96% control vents 1 1 1 1 4 1 9 9 17 5 5 6 5 6 5 37 3 3 32	38 42 16 55 219 86 197 85 25 282 282 118 1,163 494 4115 50 178 43 157 347 1,403 130 72 236	(9) 4. 4. 1. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 4. 4. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3.	feight 2 8 4 0 8 4 1 2 8 4 1 2 8 6 7 6 7 6 7 6 1 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 4 5 <td>Odds M-H, 1, 27,92 1,94 (l 2,79,2 1,94 (l 2,79,2 1,97 (l 40,45 2,64 (l 1,97 (l 1,97 (l 40,45 2,64 (l 1,97 (l 1,22 (l 2,62 (l 1,00 (l 1,23 (l 5,49 (l 1,00 (l 1,35 (l) 1,89 (l 6,04 (l 1,0,14 (l 3,55 (l))</td> <td>ratio random, 95% Cl 1.33, 2.68) 2.60, 12.35) (1.55, 501,86) 1.95, 3.95) 3.81, 9.20) 1.80, 2.68) 1.82, 11.49) 1.00, 3.89) (2.22, 737,97) 1.33, 5.22) 1.66, 2.28) 1.63, 4.23) 1.63, 4.23) 1.63, 4.23) 1.63, 4.23) 1.63, 4.23) 1.64, 4.25, 23.97) 1.35, 4.23) 1.50, 4.14) 2.18, 6.22) 3.31, 1.08) 1.82, 4.33) 2.94, 12.40) (1.25, 82.30) 1.75, 16.76)</td> <td>Year 1985 2000 2010 2012 2013 2013 2013 2013 2014 2014 2014 2014 2014 2014 2014 2014</td> <td></td> <td>Lower vit D in TE Od</td> <td>3 ds ratio</td> <td>Lower vit D in control</td>	Odds M-H, 1, 27,92 1,94 (l 2,79,2 1,94 (l 2,79,2 1,97 (l 40,45 2,64 (l 1,97 (l 1,97 (l 40,45 2,64 (l 1,97 (l 1,22 (l 2,62 (l 1,00 (l 1,23 (l 5,49 (l 1,00 (l 1,35 (l) 1,89 (l 6,04 (l 1,0,14 (l 3,55 (l))	ratio random, 95% Cl 1.33, 2.68) 2.60, 12.35) (1.55, 501,86) 1.95, 3.95) 3.81, 9.20) 1.80, 2.68) 1.82, 11.49) 1.00, 3.89) (2.22, 737,97) 1.33, 5.22) 1.66, 2.28) 1.63, 4.23) 1.63, 4.23) 1.63, 4.23) 1.63, 4.23) 1.63, 4.23) 1.64, 4.25, 23.97) 1.35, 4.23) 1.50, 4.14) 2.18, 6.22) 3.31, 1.08) 1.82, 4.33) 2.94, 12.40) (1.25, 82.30) 1.75, 16.76)	Year 1985 2000 2010 2012 2013 2013 2013 2013 2014 2014 2014 2014 2014 2014 2014 2014		Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: τ^2 =129.43; χ' Test for overall effect: Z=3.91 Heterogeneity: τ^2 =235.82; χ' Test for overall effect: Z=3.91 East for overall effect: Z=3.91 East for overall effect: Z=3.91 Asian Grange et al ²³ Wilkinson et al ⁴⁵ Sasidharan et al ²⁶ Martineau et al ²⁸ Ho-Pham et al ²⁷ Kon et al ²⁷ Kim et al ⁸⁶ Chaudhary et al ²⁹ Joshi et al ⁸⁶ Hong et al ⁸⁶ Jubuis et al ⁸⁶ Jubuis et al ⁸⁶ Chaudhary et al ²⁹ Subtotal (95% CI) Total events Heterogeneity: τ^2 =0.41; χ^2 =5 Test for overall effect: Z=3.91 Arrican Weijse et al ⁸⁶ Gibney et al ²⁹ Steenhoff et al ¹¹⁰ Stabetotal (95% CI) Total events Heterogeneity: τ^2 =1.23; χ^2 =5 Test for overall effect: Z=1.51 Ethnicity unspecified Sita-Lumsden et al ⁸⁰ Nielsen et al ⁸⁰	$\begin{array}{c} 0 \ (P{<}0.0001) \\ \\ 2=713.86, \ df{=}2 \\ 8 \ (P{<}0.0001) \\ \text{s: } \chi^2{=}1.92, \ df{=} \\ \hline \\ $	27 (P<0.00 2 (P=0.38 Total 40 104 35 84 166 165 70 25 94 60 959 P=0.0001) 362 40 50 19 119 161 1,223 2,166 <0.00001) 178 72	0001); <i>P</i> =0% C E 9 9 1 1 1 1 1 1 1 1	1% 3,599 =96% Control Vents 1 1 1 1 4 1 9 09 9 17 5 9 7 5 6 5 37 3 32 4	38 42 16 55 219 86 197 85 25 282 282 118 1,163 494 115 50 178 494 157 157 347 1,403	(१) 4.4. 1.1. 5.3. 3.3. 5.5. 5.5. 5.5. 5.5. 5.5	feight 2 8 4 0 8 4 1 2 8 4 1 2 8 6 7 6 7 6 7 6 1 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 4 5 <td>Odds M-H, 0.94 ((5.56 (27.92 2.72 () 1.94 ((2.72 () 1.97 () 40.45 (2.64 () 1.22 () 2.62 () 0.62 ((10.21 1.23 () 1.23 () 0.62 () 1.02 () 1.02 () 1.03 () 1</td> <td>ratio random, 95% CI 0.33, 2.68) 2.50, 12.35; (1.55, 501.86) 0.95, 3.95) 3.81, 9.20) 3.80, 2.68) 3.85, 11.49) 1.00, 3.89) (2.22, 737, 977) 1.33, 5.22) 0.62, 2.28) 1.83, 4.23) 0.39, 0.97) (4.35, 22.397) 0.35, 4.32) 3.45, 8.75) 0.35, 4.32) 3.45, 8.75) 0.21, 4.76) 0.50, 4.14) 2.14, 4.76) 0.50, 4.14) 2.14, 10.8) 0.39, 0.97) (1.25, 82.30)</td> <td>Year 1985 2000 2002 2010 2013 2013 2013 2014 2014 2014 2014 2017 2007 2007 2013 2013 2013 2013 2013</td> <td></td> <td>Lower vit D in TE Od</td> <td>3 ds ratio</td> <td>Lower vit D in control</td>	Odds M-H, 0.94 ((5.56 (27.92 2.72 () 1.94 ((2.72 () 1.97 () 40.45 (2.64 () 1.22 () 2.62 () 0.62 ((10.21 1.23 () 1.23 () 0.62 () 1.02 () 1.02 () 1.03 () 1	ratio random, 95% CI 0.33, 2.68) 2.50, 12.35; (1.55, 501.86) 0.95, 3.95) 3.81, 9.20) 3.80, 2.68) 3.85, 11.49) 1.00, 3.89) (2.22, 737, 977) 1.33, 5.22) 0.62, 2.28) 1.83, 4.23) 0.39, 0.97) (4.35, 22.397) 0.35, 4.32) 3.45, 8.75) 0.35, 4.32) 3.45, 8.75) 0.21, 4.76) 0.50, 4.14) 2.14, 4.76) 0.50, 4.14) 2.14, 10.8) 0.39, 0.97) (1.25, 82.30)	Year 1985 2000 2002 2010 2013 2013 2013 2014 2014 2014 2014 2017 2007 2007 2013 2013 2013 2013 2013		Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: r^2 =129.43; χ' Test for overall effect: Z=3.91 Total (95% CI) Heterogeneity: r^2 =235.82; χ' Test for overall effect: Z=12 Test for overall effect: Z=22 Test for subgroup differences Study or subgroup Martineau et al ²⁸ Wilkinson et al ⁴ Sasidharan et al ²⁸ Martineau et al ²⁹ Martineau et al ²⁹ Martineau et al ²⁹ Chaudhary et al ²⁹ Joshi et al ⁶⁶ Hong et al ⁴⁶ Gibney et al ⁴⁷ Subtotal (95% CI) Total events Heterogeneity: r^2 =0.41; χ^2 =2 Test for overall effect: Z=3.90 African Wejse et al ²⁶ Gibney et al ²⁶ Subtotal (95% CI) Total events Heterogeneity: r^2 =0.41; χ^2 =2 Test for overall effect: Z=3.90 African Wejse et al ²⁶ Gibney et al ²⁶ Subtotal (95% CI) Total events Heterogeneity: r^2 =1.23; χ^2 =2 Test for overall effect: Z=1.50 Kileisen et al ²⁶ Gray et al ²⁶ Gray et al ²⁶ Gray et al ²⁶ Heterogeneity: r^2 =0.10; χ^2 =4	$\begin{array}{c} 0 \ (P<0.0001) \\ \\ 2=713.86, \ df=2 \\ 8 \ (P<0.0001) \\ \text{s: } \ \chi^2=1.92, \ df= \\ \hline \\ \textbf{B} \ events \\ \hline \ events \\ \hline \ \ events \\ \hline \ \ events \\ \hline \ events \\ \$	27 (P<0.00 22 (P=0.38 Total 40 104 35 84 166 165 70 25 94 60 959 P=0.0001) 362 40 50 192 19 119 161 1,223 2,166 <0.00001) 178 72 11 105 366 0.22); P=5	0001); P=0% C E F 9 9 1 0 3 3 4 4 2 2 2 2 2 2 5 5 5 5 5 5 5 5 5 5 5 5 5	3,599 =96% control vents 1 1 1 1 4 1 9 9 17 5 5 6 5 6 5 37 3 3 32	38 42 16 55 219 86 197 85 25 282 282 118 1,163 494 4115 50 178 43 157 347 1,403 130 72 236	(१) 4.4. 1.1. 5.3. 3.3. 5.5. 5.5. 5.5. 5.5. 5.5	feight 2 2 8 4 0 3 3 41 1 1 2 7 6 7 7 6 7 7 6 1 2 2 2 7 6 1 2 2 2 0 2 1 5	Odds M-H, 0.94 ((5.56 (27.92 2.72 () 1.94 ((2.72 () 1.97 () 40.45 (2.64 () 1.22 () 2.62 () 0.62 ((10.21 1.23 () 1.23 () 0.62 () 1.02 () 1.02 () 1.03 () 1	ratio random, 95% CI 0.33, 2.68) 2.50, 12.35; (1.55, 501.86) 0.95, 3.95) 3.81, 9.20) 3.80, 2.68; 3.85, 11.49) 1.00, 3.89; (2.22, 737, 977) 1.33, 5.22) 0.66, 2.28; 1.83, 4.23) 0.39, 0.97) (4.35, 22.37) 0.66, 2.28; 1.83, 4.23) 0.39, 0.97) (4.35, 22.37) 0.35, 4.32) 2.44, 76; 0.36, 4.14) 2.18, 6.22) 0.31, 1.08; 0.32, 4.33) 2.94, 12.40) (1.25, 82.30) 0.75, 16.76; 1.70, 4.33)	Year 1985 2000 2010 2012 2013 2013 2013 2013 2014 2014 2014 2014 2014 2014 2014 2014		Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: $r^2=129.43$; χ' Test for overall effect: Z=3.91 Heterogeneity: $r^2=235.82$; χ' Test for overall effect: Z=3.91 East for overall effect: Z=3.91 East for subgroup differences Study or subgroup Asian Grange et al ²³ Wilkinson et al ⁴³ Sasidharan et al ²³ Koo et al ⁴⁷ Chaudhary et al ³³ Ho-Pham et al ³² Koo et al ⁴⁷ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=5$ Test for overall effect: Z=4.91 Martineau et al ³⁵ Subtotal (95% CI) Total events Heterogeneity: $r^2=1.23$; $\chi^2=5$ Test for overall effect: Z=4.91 Martineau et al ³⁶ Subtotal (95% CI) Total events Heterogeneity: $r^2=1.23$; $\chi^2=5$ Test for overall effect: Z=4.91 Mastala et al ⁴⁹ Friis et al ⁴⁹ Subtotal (95% CI) Total events Heterogeneity: $r^2=1.23$; $\chi^2=5$ Test for overall effect: Z=4.91 Subtotal (95% CI) Total events Heterogeneity: $r^2=0.10$; $\chi^2=4$ Test for overall effect: Z=4.91	$\begin{array}{c} 0 \ (P<0.0001) \\ \\ 2^{2}=713.86, \ df=2 \\ 8 \ (P<0.0001) \\ \text{s: } \chi^{2}=1.92, \ df= \\ \hline \mathbf{TB} \\ \hline \mathbf{Events} \\ \hline \mathbf{FB} \\ \hline \mathbf{Events} \\ \\ 9 \\ 9 \\ 69 \\ 16 \\ 60 \\ 8 \\ 42 \\ 73 \\ 51 \\ 11 \\ 83 \\ 33 \\ 455 \\ 35.04, \ df=10 \ (f \\ 6 \ (P<0.0001) \\ \hline 31 \\ 6 \\ 155 \\ 15 \\ 19 \\ 68 \\ 31 \\ 356 \\ 0 \ (P=0.13) \\ \hline 167 \\ 9 \\ 60 \\ 245 \\ 4.37, \ df=3 \ (P=0) \\ 5 \ (P<0.0001) \\ \hline \end{array}$	27 (P<0.00 22 (P=0.38 Total 40 104 35 84 166 165 70 25 94 60 959 P=0.0001) 362 40 50 192 19 119 161 1,223 2,166 <0.00001) 178 72 11 105 366 0.22); P=5	0001); <i>P</i> =0% C E 9 9 1 1 1 2 2 2 3 3 4 4 0 2 2 5 5 5 5 5 5 5 5	1% 3,599 96% control vents 1 1 1 1 1 1 1 9 9 17 5 5 5 6 5 37 3 32 4 10	38 42 16 55 219 86 197 85 25 282 282 118 1,163 494 4115 50 178 43 157 347 1,403 130 72 236	(१) 4.4. 1.1. 5.3. 3.3. 5.5. 5.5. 5.5. 5.5. 5.5	feight 2 8 4 0 3 4 1 4 2 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 7 6 7 7 7 7 6 7	Odds M-H, 0.94 ((5.56 () 27.92 1.94 ((2.72 () 2.72 () 2.72 () 1.97 () 1.97 () 1.97 () 2.64 () 1.97 (2 1.97 () 2.64 () 1.22 () 2.62 () 0.62 ((1.23 () 1.24 (ratio random, 95% CI 0.33, 2.68) 2.50, 12.35; (1.55, 501.86) 0.95, 3.95) 3.81, 9.20) 3.80, 2.68; 3.85, 11.49) 1.00, 3.89; (2.22, 737, 977) 1.33, 5.22) 0.66, 2.28; 1.83, 4.23) 0.39, 0.97) (4.35, 22.37) 0.66, 2.28; 1.83, 4.23) 0.39, 0.97) (4.35, 22.37) 0.35, 4.32) 2.44, 76; 0.36, 4.14) 2.18, 6.22) 0.31, 1.08; 0.32, 4.33) 2.94, 12.40) (1.25, 82.30) 0.75, 16.76; 1.70, 4.33)	Year 1985 2000 2010 2012 2013 2013 2013 2013 2014 2014 2014 2014 2014 2014 2014 2014		Lower vit D in TE Od	3 ds ratio	Lower vit D in control
Heterogeneity: $r^2=129.43$; χ' Test for overall effect: Z=3.91 Heterogeneity: $r^2=235.82$; χ' Test for overall effect: Z=3.91 East for overall effect: Z=3.91 East for overall effect: Z=3.91 Asian Grange et al ²³ Wilkinson et al ⁴⁵ Sasidharan et al ²³ Martineau et al ²³ Ho-Pham et al ²² Koo et al ²⁷ Kim et al ⁸⁶ Chaudhary et al ²⁹ Joshi et al ⁸⁶ Jobuis et al ⁸⁶ Jobuis et al ⁸⁶ Jobuis et al ⁸⁶ Heterogeneity: $r^2=0.41$; $\chi^2=5$ Test for overall effect: Z=3.91 Arrican Weijse et al ⁸⁶ Gibney et al ²⁹ Nansera et al ⁴⁶ Steenhoff et al ¹¹² Conesa-Botella et al ¹²⁵ Total events Heterogeneity: $r^2=1.23$; $\chi^2=5$ Test for overall effect: Z=1.51 Ethnicity unspecified Sita-Lumsden et al ¹⁸⁰ Nielsen et al ¹⁸⁰ Nielsen et al ¹⁸⁰ Subtotal (95% CI) Total events Heterogeneity: $r^2=1.23$; $\chi^2=5$ Test for overall effect: Z=1.51 Ethnicity unspecified Sita-Lumsden et al ¹⁸⁰ Nielsen et al ¹⁸⁰ Nielsen et al ¹⁸⁰ Nielsen et al ¹⁸⁰ Nielsen et al ¹⁸⁰ Subtotal (95% CI)	$\begin{array}{c} 0 \ (P<0.0001) \\ \\ 2=713.86, \ df=z \\ 8 \ (P<0.0001) \\ \text{s: } \chi^2=1.92, \ df= \\ \hline \\ \textbf{B} \ events \\ \hline \ events \\ \hline \ \ events \\ \hline \ \ events \\ \hline \ events \\ \hline \ \ events \\ \hline \ \ events \\ \hline \ events \\ \hline \ events \\ \hline \ events \\ \hline \ \ events \\ \hline \ \ events \\ \hline \ events $	27 (P<0.00 2 (P=0.38 Total 40 104 35 84 166 165 70 25 94 60 959 P=0.0001) 362 40 50 199 191 1,223 2,166 <0.00001) 178 72 11 1,233 366 0.22); P=3 3,491	0001); P= B), P=0% C E 9 9 1 1 2 2 2 2 5 5 5 7 7 7 7 7 7 7 7 1 5 5 7 7 1 5 5 7 7 1 5 5 7 9 9 1 1 0 0 3 3 4 2 2 2 2 2 1 5 5 7 9 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1	1% 3,599 96% Control vents 1 1 1 1 1 1 4 1 9 9 9 17 5 9 7 5 6 5 37 3 32 4 10 64	38 42 16 55 219 85 282 118 1,163 494 115 50 178 9 3 494 115 50 178 236 255 693	(१) 4.4 4.1.1 5.3 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5	feight 2 8 4 0 3 4 1 4 2 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 7 6 7 7 7 7 6 7	Odds M-H, 0.94 ((5.56 () 27.92 1.94 ((2.72 () 2.72 () 2.72 () 1.97 () 1.97 () 1.97 () 2.64 () 1.97 (2 1.97 () 2.64 () 1.22 () 2.62 () 0.62 ((1.23 () 1.24 (ratio random, 95% Cl 0.33, 2.68) 2.50, 12.35) (1.55, 501.86) 0.95, 3.95) 3.81, 9.20) 3.80, 2.68) 3.85, 11.49) 1.00, 3.89) (2.22, 737, 97) 1.63, 4.22) 0.66, 2.28) 1.63, 4.23) 0.39, 0.97) (4.35, 22, 97) 0.35, 4.22) 0.35, 4.23) 0.35, 4.23) 0.35, 4.23) 0.35, 4.23) 0.34, 58, 75) 1.21, 4.76) 1.26, 4.23) 1.21, 4.76) 1.26, 4.23) 1.21, 4.76) 1.21, 4.76) 1.22, 4.33) 2.94, 12.40) (1.25, 82, 30) 1.75, 16.76) 1.70, 4.33) 2.29, 6.81)	Year 1985 2000 2010 2012 2013 2013 2013 2013 2014 2014 2014 2014 2014 2014 2014 2014		Lower vit D in TE Od	3 ds ratio	Lower vit D in control

Figure 2 (A) Forest plot of comparison of vitamin D level (serum 25-hydroxyvitamin D [25(OH)D]) in TB patients vs control: overall effect for continuous outcome using a random-effect model. (B) Forest plot of association between VDD and risk of TB: overall effect for dichotomous outcome using a random-effect model. The diamonds stand for pooled effect.

Abbreviations: TB, tuberculosis; vit, vitamin; VDD, vitamin D deficiency; SD, standard deviation; CI, confidence interval; df, degrees of freedom; IV, independent variable.

difference for the African population (MD =–6.05; 95% CI =[-20.54, -8.43]; P=0.41; P=98) (Figure 2A). We found a similar result when the same analysis was performed excluding studies where cases and controls were subjects with other diseases such as HIV and diabetes, or where control subjects had LTBI (data not shown).

For our analysis on VDD and risk of TB, a total of 23 studies with 3,491 TB cases and 3,259 control subjects were included (Figure 2B).^{1,2,4,5,11,12,14,23,28,30,32–37,39,40–43,46,47} Our analysis showed that VDD was significantly associated with an increased risk of TB (OR =2.57; 95% CI =[1.74, 3.80]; P < 0.00001; $I^2=83$) (Figure 2B). Subgroup analysis revealed similar result for the Asian population (OR =2.62; 95% CI =[1.63, 4.23]; P < 0.0001; $I^2=71$); however, VDD was not associated with an increased risk of TB in the African population (OR =1.89; 95% CI =[0.82, 4.33]; P=0.13; $I^2=91$) (Figure 2B). Results were similar when the same analysis was performed excluding studies where

cases and controls were subjects with other diseases such as HIV and diabetes, or where control subjects had LTBI (data not shown).

VDD was more likely a risk factor for TB than its consequence

Four studies with 331 active TB cases and 326 LTBI subjects/ household contacts of active TB patients were included in our meta-analysis (Figure 3A).^{4,35,36,42} We included household contacts of active TB patients as part of our control in this analysis because they were at a high risk of becoming infected and developing TB,⁴² and a meta-analysis by Fox et al⁵³ reported a high prevalence of LTBI in contacts of active TB patients (51.5%; 95% CI =[47.1%, 55.8%]; I^2 =98.9%). Our analysis revealed a trend toward a lower serum/plasma 25(OH)D level in active TB patients vs LTBI subjects/household contacts of active TB patients; however, this trend did not reach the level of statistical

Study or subgroup	TB Mean	SD	Total	Contro Mean	-		Veigh %)	t Mean difference random, 95% CI		Year			an differ ndom, 95		
	12	10.74	103	17	10.96	42 2	28.3	-5.00 (-8.91, -1.	09)	2000					
Martineau et al35	34.4	20.8	192	55	23	178 2	27.9	-20.60 (-25.08, -	-16.12)	2011			+		
Gray et al ³⁶	29.6	11.16	11	35.9	19.34	81 2	24.9	-6.30 (-14.13, 1.	,	2012					
Joshi et al56	37.14	19.05	25	38.1	28.57	25 1	18.9	-0.96 (-14.42, 12	2.50)	2013			-		
Total (95% CI)			331			326 1	100	-8.92 (-18.62, 0.	79)				•		
Heterogeneity: τ^2 =				P<0.00001); /2=90%						-	-			
Test for overall effe	ect: Z=1	.80 (<i>P</i> =0	.07)								-100	-50	0	50	1
											Lov	ver vit D in	тв	Higher vit D in	гв
Study or subgroup	TB Even	its T	otal	LTBI Events	Total	Weigh (%)		Odds ratio M–H, random, 95% Cl	Year				ratio M– I n, 95% C		
Wilkinson et al⁴	69	1	04	11	42	22.4		5.56 (2.50, 12.35)	2000				-	_	
Gibney et al ²	31	4		27	81	20.4		6.89 (2.87, 16.51)	2008						
Martineau et al ³⁵	155		92	77	178	33.1		5.49 (3.45, 8.75)	2011						
Gray et al ³⁶	9	1	1	52	81	9.0		2.51 (0.51, 12.41)	2012			-			
Joshi et al ⁵⁶	11	2		10	25	15.1		1.18 (0.38, 3.63)	2013				•		
Total (95% CI)		3	72		407	100		4.26 (2.48, 7.30)					.	•	
Total events	275			177											
Heterogeneity: τ^2 = Test for overall effe					8%				C	► 0.01	0.1		1	10	
	001. 2 0	.27 (7 -0								V	DD lowered	I TB risk	VD	D increased TB ri	sk
Study or subgroup	TST conversion or TBIC		ersion	Contro	bl	Wei (%)		Odds ratio M–H, fixed, 95% Cl	Year			Odds ra fixed, 9	atio M–H, 5% Cl	,	
	E١	/ents	Total	Events	s Tota										
Arnedo-Pena et al			11	29	82	34.1		3.20 (0.86, 11.84)	2011				+-		
Ganmaa et al49	15	5	16	77	104	17.5	5	5.26 (0.66, 41.73)	2012			-	+	•	
Arnedo-Pena et al	57 11		18	50	180	48.3	3	4.09 (1.50, 11.13)	2014				-	-	
Total (95% CI)			45		366	100		3.99 (1.88, 8.45)						•	
Total events	33	3		156											
Heterogeneity: χ^2				0%						0.01	0,1		1	10	100
Test for overall effe	ect: Z=3	.01 (P=0	.0003)								VDD decre			D increased risk	

Figure 3 (A) Forest plot of comparison of serum 25(OH)D level in active TB patients vs LTBI subjects/household contacts of active TB patients: overall effect for continuous outcome using a random-effect model. (B) Forest plot of association between VDD and risk of developing active TB in LTBI subjects or household contacts of TB patients: overall effect for dichotomous outcome using a random-effect model. (C) Forest plot of association between VDD and risk of TST conversion/TBIC: overall effect for dichotomous outcome using a fixed-effect model. The diamonds stand for pooled effect.

Abbreviations: TB, tuberculosis; LTBI, latent TB infection; vit, vitamin; VDD, vitamin D deficiency; TST, tuberculin skin test; TBIC, TB infection conversion; SD, standard deviation; CI, confidence interval; *df*, degrees of freedom; IV, independent variable.

significance (MD =-8.92; 95% CI =[-18.62, 0.79]; *P*=0.07; *I*²=90) (Figure 3A).

VDD was significantly associated with an increased risk of developing active TB in LTBI subjects/ household contacts of TB patients

Five studies with 372 active TB patients and 407 LTBI subjects/household contacts of active TB patients were included in our analysis (Figure 3B).^{2,4,35,36,42} VDD was positively and significantly associated with an increased risk of developing active TB in LTBI subjects/household contacts of active TB patients (OR =4.26; 95% CI =[2.48, 7.30]; P < 0.00001; P = 48%) (Figure 3B).

VDD was significantly associated with an increased risk of TST conversion/TBIC

Our meta-analysis here included three studies with 45 cases with TST conversion/TBIC and 366 control subjects without

TST conversion/TBIC (Figure 3C).^{48–50} Our analysis using a fixed-effect model revealed significant association between VDD and an increased risk of TST conversion/ TBIC (OR =3.99; 95% CI =[1.88, 8.45]; P=0.0003; P=0) (Figure 3C).

Vitamin D, TB, and HIV

No significant vitamin D level difference in HIV-TBcoinfected African patients vs African HIV patients without active TB, and VDD was not associated with an increased risk of TB in African HIV-infected patients

Our meta-analysis comparing vitamin D level in HIV-TB-coinfected patients vs HIV patients without active TB included four studies on the African population with 260 HIV-TB-coinfected cases and 164 control HIV subjects without active TB (Figure 4A).^{11,12,14,35} Serum/plasma 25(OH)D level in HIV-TB-coinfected African patients was not

1	Study or subgroup		TB Mean	SD		Contro Mean		Total		Mean difference IV, random, 95% CI	Year	Mean difference IV random, 95% Cl	
	African Nansera et al ¹⁴ Martineau et al ³⁵ HIV-ini Steenhoff et al ¹¹ Conesa-Botella et al ¹² H Subtotal (95% CI) Heterogeneity: τ ² =151.7 Test for overall effect: Z	IIV-infected 71; $\chi^2=24.7$	1, <i>df</i> =3	27.5 19.1 11.19 32.59 8 (<i>P</i> <0.0	99 19 92 260	54.7 38.3 79	27.5 27.4 10.15 28.15		24.3 26.8 27.1 21.8 100	-10.00 (-20.78, 0.78) -26.00 (-33.25, -18.75) -3.20 (-9.99, 3.59) 2.00 (-12.02, 16.02) -9.83 (-22.87, 3.22)	2011 2011 2012 2012	+	
	Total (95% CI)				260	2001		164	100	-9.83 (-22.87, 3.22)		•	
	Heterogeneity: $\tau^2=151.7$			s (P<0.0	101); <i>1</i> 2=8	38%					-1	00 -50 0	50 1
	Test for overall effect: Z Test for subgroup differe	•	,	ble									er vit D HIV
3	Study or subgroup		TB Eve	ents	Total	Cont Even		Total	Weight (%)	t Odds ratio M–H, random, 95% Cl	Year	Odds ratio M–H, random, 95% Cl	
	African Martineau et al ³⁵ HIV-inf Nansera et al ¹⁴ Conesa-Botella et al ¹² H Steenhoff et al ¹¹ Subtotal (95% CI) Total events	IIV-infected	15 121		99 50 92 19 260	39 5 3 15 62		75 50 20 19 164	32.6 24.3 23.0 20.1 100	5.60 (2.72, 11.56) 1.23 (0.35, 4.32) 1.10 (0.29, 4.24) 1.00 (0.21, 4.76) 1.89 (0.69, 5.14)	2011 2011 2012 2012	-	
	Heterogeneity: τ^2 =0.67; Test for overall effect: Z			=0.03);									
	Total (95% CI) Total events		121		260	62		164	100	1.89 (0.69, 5.14)		-	
	Heterogeneity: τ^2 =0.67;	$\chi^2 = 8.67 d$			l ² =65%	02							+
	Test for overall effect: Z		•	-0.00), 1	-0070						0.0		10 1 Icreased
	Test for subgroup differe		'	ble									risk
;	Study or subgroup	TB-IRIS Mean	SD	Total	Contr Mean		I	「otal	Weight (%)	Mean difference IV, fixed, 95% Cl	Year	Mean difference IV fixed, 95% CI	',
	African Nansera et al ¹⁴ Conesa-Botella et al ⁵¹ Conesa-Botella et al ¹² Subtotal (95% CI) Heterogeneity: χ^2 =0.11,	22.5 7 64.5 3	30 7.26 33.64 .94); / ² :	15 23 39 77 =0%	65 28 72.1	17.5 7.19 20.8) 2 31 5	35 29 53 1 17	5.1 85.6 9.4 100	-5.00 (-21.25, 11.25) -5.50 (-9.46, -1.54) -7.60 (-19.55, 4.35) -5.67 (-9.33, -2.01)	2011 2012 2012	•	
	Test for overall effect: Z	=3.04 (<i>P</i> =0	.002)										
	Total (95% CI) Heterogeneity: $\chi^2=0.11$, Test for overall effect: Z Test for subgroup differe	=3.04 (P=0	.002)				1	117	100	-5.67 (-9.33, -2.01)	+ -10 V	00 −50 0 /it D decreased risk Vit D inc	50 1 reased ris

Figure 4 (A) Forest plot of comparison of serum 25(OH)D level in HIV-TB-coinfected patients vs HIV patients without active TB: overall effect for continuous outcome using a random-effect model. (B) Forest plot of association between VDD and risk of TB in HIV-infected patients: overall effect for dichotomous outcome using a random-effect model. (C) Forest plot comparing 25(OH)D level in HIV-TB-coinfected patients receiving ART who developed TB-IRIS vs HIV-TB-coinfected patients receiving ART who did not develop TB-IRIS: overall effect for continuous outcome using a fixed-effect model. The diamonds stand for pooled effect.

Abbreviations: HIV, human immunodeficiency virus; TB, tuberculosis; ART, antiretroviral therapy; TB-IRIS, TB-associated immune reconstitution inflammatory syndrome; vit, vitamin; VDD, vitamin D deficiency; SD, standard deviation; CI, confidence interval; *df*, degrees of freedom; IV, independent variable.

significantly different from HIV-infected African patients without active TB (MD =-9.83; 95% CI =[-22.87, 3.22]; P=0.14; $I^2=88$) (Figure 4A).

The same four studies on African population with 260 HIV-TB-coinfected cases and 164 control HIV subjects without active TB were included in our analysis on the association between VDD and risk of TB in HIV-infected patients (Figure 4B).^{11,12,14,35} There was no significant association between VDD and risk of TB in African HIV-infected patients (OR =1.89; 95% CI =[0.69, 5.14]; P=0.22; P=65) (Figure 4B).

Significantly lower vitamin D level in HIV-TBcoinfected African patients receiving ART who developed TB-IRIS vs those who did not develop TB-IRIS

Three studies with 77 HIV-TB-coinfected African cases receiving ART who developed TB-IRIS and 117 African control patients who did not develop TB-IRIS were included in this analysis (Figure 4C).^{12,14,51} HIV-TB-coinfected African cases receiving ART who developed TB-IRIS had a significantly lower vitamin D level vs those who did not develop TB-IRIS (MD =–5.67; 95% CI =[–9.33, –2.01]; P=0.002; I²=0) (Figure 4C).

Anti-TB treatment and vitamin D level

Anti-TB treatment did not affect vitamin D level in TB patients receiving the treatment

Three studies with 224 TB patients receiving 1–4 months of anti-TB treatments^{25,37,52} and four studies with 391 TB patients receiving full course of anti-TB treatment^{1,25,37,46} were included in our analysis on whether anti-TB treatment affected vitamin D level in TB patients receiving the treatment (Figure 5A and B). Neither 1–4 months of anti-TB treatment (MD =1.47; 95% CI =[-2.79, 5.73]; P=0.50; P=57) (Figure 5A) nor a full course of anti-TB treatment (MD =5.03; 95% CI =[-3.20, 13.25]; P=0.23; P=86) (Figure 5B) affected 25(OH)D level significantly.

TB patients still had a significantly lower vitamin D level after completion of anti-TB treatment than controls without TB

Four studies with 327 TB cases after completion of anti-TB treatment and 592 control subjects without TB were included (Figure 5C).^{1,25,37,46} Vitamin D level was still significantly lower in TB patients after completion of their anti-TB treatment vs control subjects without TB (MD =–8.05; 95% CI =[-13.56, -2.54]; P=0.004; P=68) (Figure 5C), especially for the Asian population

(MD =-9.36; 95% CI =[-15.23, -3.48]; *P*=0.002; *I*²=80) (Figure 5C).

A trend of higher 1,25(OH)2D3 level in TB patients vs controls without TB

Although serum 25(OH)D is the commonly used measure of vitamin D status in a subject,⁷ 1,25(OH)2D3 is the actual bioactive form of vitamin D that induces antimicrobial response,⁷ and therefore we performed a meta-analysis comparing 1,25(OH)2D3 level in TB subjects vs controls without TB. Four studies with 160 TB cases and 338 control subjects without TB were included (Figure 6).^{22,29,31,45} There was a trend toward higher 1,25(OH)2D3 level in TB patients vs controls; however, this trend did not reach the level of statistical significance (SMD =1.02; 95% CI =[-0.09, 2.14]; P=0.07; l^2 =95) (Figure 6).


Between-studies heterogeneity and publication bias

Between-studies heterogeneity varied from none to high for our meta-analyses with *l*² values ranging from 0 to 96 (Figures 2A and B, 3A–C, 4A–C, 5A–C, and 6). Furthermore, funnel plots for all of our meta-analyses were symmetrical, suggesting the presence of none or very little publication bias in our analyses (data not shown).

Discussion

Our meta-analysis on the association between vitamin D and TB showed a significantly lower level of vitamin D in TB patients vs controls and that VDD was positively associated with an increased risk of TB, which is consistent with the results of the meta-analysis by Nnoaham et al.¹³ In the subgroup analysis, although we found similar results for the Asian population, such an association was lacking in the African population even when we excluded studies where cases and controls had other diseases such as HIV and diabetes, or where the control subjects had LTBI. This suggested the possibility of ethnic difference in the role of vitamin D in TB that warrants further investigation. As sunlight and diet are two major sources of vitamin D for humans,13 adequate exposure to sunlight and/or adjustment of diet to maintain proper vitamin D level in our bodies is be deemed a necessity.

As HIV-infected subjects are more susceptible to TB and have greater mortality and morbidity caused by TB,¹⁴ in order to further clarify whether vitamin D played any role in occurrence and deterioration of TB in HIV-infected subjects, we also analyzed the association between vitamin D level/ VDD and TB in HIV-infected subjects and the association



Study or subgroup	TB Mean	SD	Total	Contro Mean		Total	Weight (%)	Std mean difference IV, random, 95% CI	Year	Std mean differer IV, random, 95% (
Asian											
Yonemura et al ²⁹	45.9	31.5	6	11.8	7.5	110	22.7	3.43 (2.50, 4.37)	2004	•	
Selvaraj et al ³¹	92.5	50.39	65	62.5	43.78	60	26.4	0.63 (0.27, 0.99)	2009	+	
Gao et al45	365.9	235.7	74	464.3	335.6	153	26.7	-0.32 (-0.60, -0.04)	2014	•	
Subtotal (95% Cl	I)		145			323	75.8	1.16 (-0.24, 2.55)			
Heterogeneity: τ^{2} Test for overall eff				°<0.0000	01); /²=9	7%					
Ethnicity unspec	cified										
Davies et al ²²	35.7	10.48	15	28.7	9.75	15	24.2	0.67 (-0.07, 1.41)	1985	•	
Subtotal (95% Cl	I)		15			15	24.2	0.67 (-0.07, 1.41)			
Heterogeneity: no Test for overall eff			0.07)								
Total (95% CI)			160			338	100	1.02 (–0.09, 2.14)			
Heterogeneity: τ^2				P<0.0000	01); /²=9	5%			H		
Test for overall eff				-1 (P-0	55): <i>1</i> 2-	0%			-100	-50 0	50 10
Test for subgroup	uneren	ιες. χ-=	0.30, 01	- i (P=0	.55), 1-=	U 70				Lower 1,25(OH)2D3 in TB 1	Higher ,25(OH)2D3 in TB

Figure 6 Forest plot of comparison of the level of the vitamin D metabolite – serum/plasma 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in TB patients vs control without TB: overall effect for continuous outcome using a random-effect model.

Note: The diamonds stand for pooled effect.

Abbreviations: TB, tuberculosis; SD, standard deviation; CI, confidence interval; df, degrees of freedom; IV, independent variable.

between vitamin D level and risk of developing TB-IRIS in HIV-TB-coinfected patients receiving ART. Our analysis showed that there was no significant difference in vitamin D level in HIV-TB-coinfected African patients vs African HIV patients without active TB and that VDD was not associated with an increased risk of TB in African HIV-infected patients. However, a significantly lower vitamin D level was found in HIV-TB-coinfected African patients receiving ART who developed TB-IRIS vs those who did not. In view of the fact that our analysis showed lack of association between vitamin D and TB in the African population, such lack of association between vitamin D and TB in the HIV-infected African population should be interpreted with caution as to whether it represents a true lack of association in HIV-infected subjects; studies on HIV-infected subjects of other ethnicities are needed to confirm these results. However, if such a lack of association is indeed true, Steenholf et al¹¹ suggested that as HIV-infected subjects are already immunocompromised, it is possible that any immune response induced by vitamin D would also be compromised, thus masking any role vitamin D played in fighting TB; this, along their observation that HIV-infected subjects without TB were already plagued with VDD, could provide a possible explanation for such a lack of association between vitamin D and TB in HIV-infected subjects. On the other hand, our finding that HIV-TB-coinfected subjects who developed TB-IRIS (a paradoxical worsening of TB after initial improvement upon TB treatment after ART initiation or manifestation of TB clinically not apparent before ART initiation) had a lower vitamin D level that those who did not suggest that vitamin D was somehow still involved

in TB occurrence and progression in HIV-infected patients. Conesa-Botella et al⁵¹ reported an association between VDD and elevated proinflammatory cytokine and that corticosteroid therapy could modify patients' inflammatory profile and possibly even reduce the severity of TB-IRIS symptom and suggested vitamin D supplement prior to ART initiation to determine whether it decreased TB-IRIS incidence. Meanwhile, as only a limited number of studies with limited sample sizes were included in our analyses, more studies with larger sample sizes are needed to further elucidate whether there is any association between VDD and TB/TB-IRIS.

Also, our analysis found a significant association between VDD and TB, but it did not tell us whether VDD was a risk factor or a consequence of TB; however, our analysis revealed that VDD was significantly associated with an increased risk of developing active TB in LTBI subjects/household contacts of TB patients, that VDD was significantly associated with an increased risk of TST conversion/TBIC, and that the trend toward a lower vitamin D level in active TB patients vs LTBI subjects/household contacts of active TB patients did not reach statistical significance. These results suggested that VDD was more likely a risk factor for TB rather than its consequence. Had VDD been a manifestation of malnutrition generally associated with TB, we would expect a more significant difference in vitamin D level between active TB patients vs LTBI subjects/household contacts of active TB patients and VDD would not have been significantly associated with an increased risk of LTBI developing into active TB or TST conversion/TBIC. On the contrary, our result suggested that vitamin D was possibly involved in the early stage of TB infection and symptom manifestation; in addition, it has been shown that 1,25(OH)2D3 activates VDR signaling and induces antimicrobial responses such as induction of autophagy, phagolysosomal fusion, release and activation of the antimicrobial peptide cathelicidin, and killing of intracellular M. tuberculosis.7-9 All of these results pointed to the fact that VDD is more likely a risk factor for TB. This possibility was further strengthened by our results that anti-TB treatment did not significantly affect vitamin D level in TB patients receiving the treatment and that TB subjects after completion of anti-TB treatment still had a significantly lower vitamin D level than control subjects without TB. This was because if VDD had been a consequence of TB, we would expect a significantly elevated vitamin D level in TB subjects after effective anti-TB treatment. Overall, our analyses indicated that VDD was most likely a risk factor for TB.

Since our analysis indicated that VDD was most likely a risk factor for TB, this raises a question of whether vitamin D supplement would be beneficial to TB prevention and treatment. The meta-analysis by Xia et al⁵⁴ in 2012 reported that vitamin D supplementation did not show a significant benefit to TB treatment; however, the meta-analysis did not address the question of whether it would be beneficial to TB prevention. Rigorously controlled studies will be needed to further determine whether vitamin D supplementation would be beneficial.

Because 1,25(OH)D3 is the bioactive form of vitamin D,⁷ we also analyzed the level of 1,25(OH)2D3 in TB subjects vs controls and found a trend of higher 1,25(OH)2D3 level in TB patients vs controls without TB. Selvaraj et al³¹ postulated that this possible increase in 1,25(OH)2D3 could be because of CYP27B1 expression upregulation that led to increased conversion of 25(OH)D to 1,25(OH)2D3, which could then cause 25(OH)D deficiency because of its increased use. However, if this is the case, it would mean that VDD would be a consequence of TB rather than one of its causes and would be inconsistent with our previous conclusions. On the other hand, as only four studies with limited sizes were included in our analysis, this result is far from certain, and more studies are needed to confirm or refute this result.

There are certain strengths and limitations in our study. Its strength lies in the fact that it was a comprehensive analysis of multiple aspects of the relationship between vitamin D and TB and helped to answer the question of whether vitamin D was one of the causes or consequences of TB, and our analysis included all relevant available studies of reasonable quality to ensure that the resulting picture was as complete as possible. However, our study also has certain limitations. For some of our analyses, the number of relevant studies was limited and their sample sizes were small, which undoubtedly would affect the certainty of some of our results. Furthermore, because different studies used different standards for VDD, such inconsistency in VDD definition would also affect our results.

Conclusion

Our analyses revealed a significantly lower vitamin D level in TB subjects and that VDD was associated with more risk of TB. VDD is more likely a risk factor for TB than its consequence, and more studies are needed to determine whether vitamin D supplement is beneficial to TB prevention and treatment.

Disclosure

The authors report no conflicts of interest in this work.

References

- Kim JH, Park JS, Cho YJ, et al. Low serum 25-hydroxyvitamin D level: an independent risk factor for tuberculosis? *Clin Nutr.* 2014;33(6): 1081–1086.
- Gibney KB, MacGregor L, Leder K, et al. Vitamin D deficiency is associated with tuberculos and latent tuberculos is infection in immigrants from sub-Saharan Africa. *Clin Infect Dis.* 2008;46(3):443–446.
- Chocano-Bedoya P, Ronnenberg AG. Vitamin D and tuberculosis. *Nutr Rev.* 2009;67(5):289–293.
- Wilkinson RJ, Llewelyn M, Toossi Z, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in West London: a case-control study. *Lancet*. 2000; 355(9204):618–621.
- Wejse C, Olesen R, Rabna P, et al. Serum 25-hydroxyvitamin D in a West African population of tuberculosis patients and unmatched healthy controls. *Am J Clin Nutr.* 2007;86(5):1376–1383.
- Ustianowski A, Shaffer R, Collin S, Wilkinson RJ, Davidson RN. Prevalence and associations of vitamin D deficiency in foreign-born persons with tuberculosis in London. *J Infect*. 2005;50(5):432–437.
- 7. Realegeno S, Modlin RL. Shedding light on the vitamin D-tuberculosis-HIV connection. *Proc Natl Acad Sci U S A*. 2011;108:18861–18862.
- Liu PT, Stenger S, Li H, et al. Toll-like receptors triggering of a vitamin D mediated anti-microbical response. *Science*. 2006;311(5768): 1770–1773.
- Adams JS, Ren S, Liu PT, et al. Vitamin D directed rheostatic regulation of monocyte antibacterial responses. *J Immunol.* 2009;182(7): 4289–4295.
- Friis H, Range N, Pedersen ML, et al. Hypovitaminosis D is common among pulmonary tuberculosis patients in Tanzania but is not explained by the acute phase response. *J Nutr.* 2008;138(12):2474–2480.
- Steenhoff AP, Redwood A, Pettifor JM, et al. Vitamin D status in HIVinfected patients with and without tuberculosis: a pilot study. *J Acquir Immune Defic Syndr.* 2012;61(2):e21–e23.
- 12. Conesa-Botella A, Goovaerts O, Massinga-Loembé M, et al. Low prevalence of vitamin D deficiency in Ugandan HIV-infected patients with and without tuberculosis. *Int J Tuberc Lung Dis.* 2012;16(11): 1517–1521.
- Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. *Int J Epidemiol.* 2008; 37:(1)113–119.

- Nansera D, Graziano FM, Friedman DJ, Bobbs MK, Jones AN, Hansen KE. Vitamin D and calcium levels in Ugandan adults with human immunodeficiency virus and tuberculosis. *Int J Tuberc Lung Dis*. 2011; 15(11):1522–1527.
- Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011], Section 7.7.3.5 Medians and interquartile ranges. The Cochrane Collaboration, 2011. Available from: http://handbook.cochrane.org/
- Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011], Section 7.7.3.6 Ranges. The Cochrane Collaboration, 2011. Available from: http:// handbook.cochrane.org/
- Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011], Section 7.7.3.2 Obtaining standard deviations from standard errors and confidence intervals for group means. The Cochrane Collaboration, 2011. Available from: http://handbook.cochrane.org/
- Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in metaanalysis. Ottawa, ON: Ottawa Health Research Institute; 2004.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.
- Higgins J, Thompson S, Deeks J, Altman D. Statistical heterogeneity in systematic reviews of clincial trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy. 2002;7(1):51–61.
- Navarro-Mateu F, Escámez T, Koenen KC, Alonso J, Sánchez-Meca J. Meta-analyses of the 5-HTTLPR polymorphism and post-traumatic stress disorder. *PLoS One*. 2013;8(6):e66227.
- Davies PD, Brown RC, Woodhead JS. Serum concentrations of vitamin D metabolites in untreated tuberculosis. *Thorax.* 1985;40(8):187–190.
- Grange JM, Davies PD, Brown RC, Woodhead JS, Kardjito T. A study of vitamin D levels in Indonesian patients with untreated pulmonary tuberculosis. *Tubercle*. 1985;66(3):187–191.
- Davies PD, Church HA, Brown RC, Woodhead JS. Raised serum calcium in tuberculosis patients in Africa. *Eur J Respir Dis.* 1987;71(5): 341–344.
- Davies PD, Brown RC, Church HA, Woodhead JS. The effect of antituberculosis chemotherapy on vitamin D and calcium metabolism. *Tubercle*. 1987;68(4):261–266.
- Davies PD, Church HA, Bovornkitti S, Charumilind A, Byrachandra S. Altered vitamin D homeostasis in tuberculosis. *Int Med Thailand*. 1988;4:45–47.
- Chan TY, Poon P, Pang J, et al. A study of calcium and vitamin D metabolism in Chinese patients with pulmonary tuberculosis. *J Trop Med Hyg.* 1994;97(1):26–30.
- Sasidharan PK, Rajeev E, Vijayakumari V. Tuberculosis and vitamin D deficiency. J Assoc Physicians India. 2002;50:554–558.
- Yonemura K, Ohtake T, Matsushima H, Fujigaki Y, Hishida A. High ratio of 1,25-dihydroxyvitamin D3 to parathyroid hormone in serum of tuberculous patients with end-stage renal disease. *Clin Nephrol.* 2004;62(3):202–207.
- Sita-Lumsden A, Lapthorn G, Swaminathan R, Milburn HJ. Reactivation of tuberculosis and vitamin D deficiency: the contribution of diet and exposure to sunlight. *Thorax*. 2007;62(11):1003–1007.
- Selvaraj P, Prabhu Anand S, Harishankar M, Alagarasu K. Plasma 1,25 dihydroxy vitamin D3 level and expression of vitamin d receptor and cathelicidin in pulmonary tuberculosis. *J Clin Immunol*. 2009;29(4):470–478.
- Ho-Pham LT, Nguyen ND, Nguyen TT, et al. Association between vitamin D insufficiency and tuberculosis in a Vietnamese population. *BMC Infect Dis.* 2010;10:306.
- Martineau AR, Leandro AC, Anderson ST, et al. Association between Gc genotype and susceptibility to TB is dependent on vitamin D status. *Eur Respir J.* 2010;35(5):1106–1112.
- Nielsen NO, Skifte T, Andersson M, et al. Both high and low serum vitamin D concentrations are associated with tuberculosis: a case-control study in Greenland. Br J Nutr. 2010;104(10):1487–1491.

- Martineau AR, Nhamoyebonde S, Oni T, et al. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc Natl Acad Sci USA. 2011;108(47):19013–19017.
- Gray K, Wood N, Gunasekera H, et al. Vitamin D and tuberculosis status in refugee children. *Pediatr Infect Dis J.* 2012;31(5):521–523.
- Koo HK, Lee JS, Jeong YJ, et al. Vitamin D deficiency and changes in serum vitamin D levels with treatment among tuberculosis patients in South Korea. *Respirology*. 2012;17(5):808–813.
- Rathored J, Sharma SK, Singh B, et al. Risk and outcome of multidrugresistant tuberculosis: vitamin D receptor polymorphisms and serum 25(OH)D. *Int J Tuberc Lung Dis.* 2012;16(11):1522–1528.
- Chaudhary S, Thukral A, Tiwari S, Pratyush DD, Singh SK. Vitamin D status of patients with type 2 diabetes and sputum positive pulmonary tuberculosis. *Indian J Endocrinol Metab.* 2013;17(Suppl 3):S670–S673.
- Friis H, Range N, Changalucha J, et al. Vitamin D status among pulmonary TB patients and non-TB controls: a cross-sectional study from Mwanza, Tanzania. *PLoS One*. 2013;8(12):e81142.
- Iftikhar R, Kamran SM, Qadir A, Haider E, Bin Usman H. Vitamin D deficiency in patients with tuberculosis. *J Coll Physicians Surg Pak*. 2013;23(10):780–783.
- 42. Joshi L, Ponnana M, Penmetsa SR, Nallari P, Valluri V, Gaddam S. Serum vitamin D levels and VDR polymorphisms (BsmI and FokI) in patients and their household contacts susceptible to tuberculosis. *Scand J Immunol.* 2014;79(2):113–119.
- 43. Mastala Y, Nyangulu P, Banda RV, Mhemedi B, White SA, Allain TJ. Vitamin D deficiency in medical patients at a central hospital in Malawi: a comparison with TB patients from a previous study. *PLoS One*. 2013; 8(3):e59017.
- 44. Srinivasan A, Syal K, Banerjee D, et al. Low plasma levels of cholecalciferol and 13-cis-retinoic acid in tuberculosis: implications in host-based chemotherapy. *Nutrition*. 2013;29(10):1245–1251.
- 45. Gao WW, Wang Y, Zhang XR, et al. Levels of 1,25(OH)2D3 for patients with pulmonary tuberculosis and correlations of 1,25(OH)2D3 with the clinical features of TB. *J Thorac Dis.* 2014;6(6):760–764.
- Hong JY, Kim SY, Chung KS, et al. Association between vitamin D deficiency and tuberculosis in a Korean population. *Int J Tuberc Lung Dis.* 2014;18(1):73–78.
- Jubulis J, Kinikar A, Ithape M, et al. Modifiable risk factors associated with tuberculosis disease in children in Pune, India. *Int J Tuberc Lung Dis.* 2014;18(2):198–204.
- Arnedo-Pena A, Juan-Cerdán JV, Romeu-Garcia A, et al. Latent tuberculosis infection, tuberculin skin test and vitamin D status in contacts of tuberculosis patients: a cross-sectional and case-control study. *BMC Infect Dis.* 2011;11:349.
- Ganmaa D, Giovannucci E, Bloom BR, et al. Vitamin D, tuberculin skin test conversion, and latent tuberculosis in Mongolian school-age children: a randomized, double-blind, placebo-controlled feasibility trial. *Am J Clin Nutr.* 2012;96(2):391–396.
- Arnedo-Pena A, Juan-Cerdán JV, Romeu-García MA, et al. Vitamin D status and incidence of tuberculosis infection conversion in contacts of pulmonary tuberculosis patients: a prospective cohort study. *Epidemiol Infect*. 2015;143(8):1731–1741.
- 51. Conesa-Botella A, Meintjes G, Coussens AK, et al. Corticosteroid therapy, vitamin D status, and inflammatory cytokine profile in the HIV-tuberculosis immune reconstitution inflammatory syndrome. *Clin Infect Dis.* 2012;55(7):1004–1011.
- Tostmann A, Wielders JP, Kibiki GS, Verhoef H, Boeree MJ, van der Ven AJ. Serum 25-hydroxy-vitamin D3 concentrations increase during tuberculosis treatment in Tanzania. *Int J Tuberc Lung Dis.* 2010;14(9): 1147–1152.
- Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and meta-analysis. *Eur Respir J*. 2013; 41(1):140–156.
- Xia J, Shi L, Zhao L, Xu F. Impact of vitamin D supplementation on the outcome of tuberculosis treatment: a systematic review and meta-analysis of randomized controlled trials. *Chin Med J (Engl)*. 2014;127(17): 3127–3134.

- Kim JH, Park JS, ChoYJ, et al. Low serum 25-hydroxyvitamin D level: an independent risk factor for tuberculosis? *Clin Nutr.* 2014;33(6): 1081–1086 (Epub 2013 Nov 26).
- Joshi L, Ponnana M, Penmetsa SR, Nallari P, Valluri V, Gaddam S. Serum vitamin D levels and VDR polymorphisms (BsmI and FokI) in patients and their household contacts susceptible to tuberculosis. *Sand J Immunol.* 2014;79:113–119 (Epub 2013).
- 57. Arnedo-Pena A, Juan Cerdan JV, Romeu-Garcia A, et al. Latent tuberculosis infection, tuberculin skin test and vitamin D status in contacts of tuberculosis patients: a cross-sectional and case-control study. *BMC Infect Dis.* 2011;11:349.

Drug Design, Development and Therapy

Publish your work in this journal

Drug Design, Development and Therapy is an international, peerreviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are the features of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

 $\textbf{Submit your manuscript here:} \ \texttt{http://www.dovepress.com/drug-design-development-and-therapy-journal}$

Dovepress